

PERSONAL INFORMATION **Antonius De Boer**WORK EXPERIENCE

---

- September 1982-March 1984 **Resident Internal Medicine**  
Military hospital Dr A Mathijssen (Netherlands)  
Responsible for hospitalized patients (internal medicine ward) and policlinic
- April 1984-October 1985 **Resident Internal Medicine**  
St Elizabeth Hospital (Netherlands)  
Responsible for hospitalized patients (internal medicine ward) and policlinic
- November 1985-July 1987 **researcher**  
University Leiden, Center for Biopharmaceutical Sciences (Netherlands)  
PhD project
- August 1987-June 1990 **researcher**  
Center for Human Drug Research (Netherlands)  
PhD project
- July 1990-February 1992 **Assistant Professor Clinical Epidemiology**  
University Leiden (Netherlands)  
Research and education (clinical epidemiology)
- March 1992-October 2001 **Associate Professor Pharmacotherapy**  
Utrecht University (Netherlands)  
Research, education, management
- November 2001-June 2022 **Professor of Pharmacotherapy**  
Utrecht University (Netherlands)  
Research, education. director of the School of Pharmacy (2001-2009), Head of the department of Pharmaceutical Sciences (2009-2017)
- August 2017- Present **Chairman of the Medicines Evaluation Board**  
Medicines Evaluation Board of the Netherlands (Netherlands)  
End responsibility of scientific advices and assessments of drugs in national and (de)central procedures of the MEB

EDUCATION AND TRAINING

---

- September 1974-June 1982 **Medical doctor**  
Medical School, Free University (Netherlands)
- November 1985-June 1990 **PhD**  
University Leiden (Netherlands)  
PhD in Clinical Pharmacology. Phase 1 studies in healthy volunteers
- July 1990-January 1994 **Epidemiologist**  
Epidemiological society (Netherlands)
- November 1985- 1996 **Clinical Pharmacologist**  
Dutch Society of Clinical Pharmacology and Biopharmacy (Netherlands)
- 1996- 1998 **Basic Qualification of Education**  
Utrecht University (Netherlands)

**ADDITIONAL INFORMATION****Expertise** Pharmacoepidemiology and clinical pharmacology

- Publications**
1. De Boer A, Cohen AF, Klufft C, Kroon JM, Kasper FJ, Stiekema JCJ, Breimer DD. Invloed van heparine en Org 10172 op de plasma t-PA concentraties in rust en tijdens inspanning. In: Thrombose en atherosclerose. eds. J.W. ten Cate e.a. 1988;71-5.
  2. De Boer A. Drug interactions with anticoagulant, antiplatelet and thrombolytic drugs in healthy subjects. PhD thesis, Leiden, The Netherlands 1990.
  3. Stiekema JCJ, De Boer A, Danhof M, Kroon C, Broekmans AW, Van Dinther ThG, Voerman J, Breimer DD. An interaction study of the combined medication of Org 10172, a low molecular weight heparinoid, and acenocoumarol. Haemostasis 1990;20:136-46.
  4. Kroon C, De Boer A, Hoogkamer JFW, Schoemaker HC, Van der Meer FJM, Edelbroek PM, Cohen AF. Detection of drug interactions with single dose acenocoumarol: a useful screening method? Int J Clin Pharmacol Ther Toxicol 1990;28:355-60.
  5. De Boer A, Klufft C, Cohen AF. Life style and fibrinolytic activity: a comment on clearance of plasminogen activators. Fibrinolysis 1990;4:61-3.
  6. Dooijewaard G, De Boer A, Turion PNC, Cohen AF, Breimer DD, Klufft C. Physical exercise induces enhancement of urokinase type plasminogen activator (u-PA) levels in plasma. Thromb Haemostas 1991;65:82-6.
  7. De Boer A, Stiekema JCJ, Danhof M, Breimer DD. The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172. Br J clin Pharmac 1991;32:23-9.
  8. De Boer A, Danhof M, Cohen AF, Magnani HN, Breimer DD. Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers. Thromb Haemostas 1991;66:202-7.
  9. De Boer A, Gerloff J, Klufft C, Dooijewaard G, Gunzler WA, Beier H, Van der Meer FJM, Cohen AF. Farmacokinetiek en farmacodynamiek van het recombinant pro-urokinase saruplase. In: Thrombose en atherosclerose. eds. J.W. ten Cate e.a. 1991;55-8.
  10. Dooijewaard G, De Boer A, Turion PNC, Cohen AF, Breimer DD, Klufft C. Fysieke inspanning induceert verhoogde spiegels van urokinase-type plasminogeen activator in plasma. In: Thrombose en atherosclerose. eds. J.W. ten Cate e.a. 1991;68-71.
  11. Kroon C, De Boer A, Kroon JM, Schoemaker HC, Van der Meer FJM, Cohen AF. Influence of skinfold thickness on heparin absorption. Lancet 1991;337:945-46.
  12. De Boer A, Stiekema JCJ, Danhof M, Breimer DD. The influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (LomoparanR), a low molecular weight heparinoid, in healthy volunteers. J Clin Pharmacol 1991;31:611-17.
  13. De Boer A, Stiekema JCJ, Danhof M, Moolenaar AJ, Breimer DD. Interaction study of Org 10172, a low molecular weight heparinoid, and digoxin in healthy male volunteers. Eur J Clin Pharmacol 1991;41:245-50.
  14. De Boer A, Stiekema JCJ, Danhof M, Cohen AF, Boeijinga JK, Breimer DD. Studies on interaction of a low-molecular-weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers. Antimicrob Agents Ch 1991;35:2110-15.
  15. Soons PA, De Boer A, Cohen AF, Breimer DD. Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green. Br J clin Pharmac 1991;32:697-704.
  16. Uchida E, Soons PA, De Boer A, Schoemaker HC, Cohen AF, Breimer DD. Effects of physical exercise and oral nifedipine on hepatic blood flow as assessed by a continuous infusion of indocyanin green. Thesis, Leiden 1991; pp 177-192
  17. De Boer A, Klufft C, Kasper FJ, Kroon JM, Schoemaker HC, Breimer DD, Soons PA, Cohen AF. Liver blood flow as a major determinant of the clearance of recombinant tissue-type plasminogen activator. Thromb Haemostas 1992;67:83-7.
  18. De Boer A, Kroon JM, Kroon C, Van Vliet A, Schoemaker HC, Breimer DD, Donoghue S, Cohen AF. Pronounced effects of a new thromboxane receptor antagonist (GR32191) and heparin on

bleeding time in man. *Thromb Haemostas* 1992;68:24-9.

19. Krulder JWM, De Boer A, Van den Besselaar AMPH, Cohen AF, Schoemaker HC, Briet E, Meinders AE. Diurnal rhythm in anticoagulant effect of heparin during a low dose constant rate infusion; A study in healthy volunteers. *Thromb Haemostas* 1992;68:30-2.
20. Danhof M, De Boer A, Stiekema JCJ, Magnani HM. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. *Haemostasis* 1992;22:73-84.
21. Van den Bosch JH, De Boer A, Vandenbroucke JP, Bergman W. Het familiale dysplastische nevus syndroom: het aantal nevi als risico-indicator en voorspeller. *T Soc Gezondheidsz* 1992;70:453-56.
22. Kroon C, Ten Hove WR, De Boer A, Kroon JM, Van der Pol JMJ, Harthoorn E, Schoemaker HC, Van der Meer FJM, Cohen AF. Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. *Circulation* 1992;86:1370-75.
23. De Boer A, Cohen AF, Kluit C, Kroon JM, Kasper FJ, Stiekema JCJ, Breimer DD. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise. *Thromb Haemostas* 1992;68:550-5.
24. Cohen AF, Burggraaf K, De Boer A, Kluit C. Clearance of plasminogen activators - A major determinant of plasma concentration. Therapeutic and diagnostic implications. *Annals of the New York Academy of Sciences* 1992;667:443-50.
25. De Boer A, Oosterwijk JC. De invloed van kunstmatige inseminatie met donorsperma (KID) op consanguiniteit in Nederland. In: *Advies medisch-technische aspecten van kunstmatige donorinseminatie*. Centraal Begeleidingsorgaan voor de Intercollegiale toetsing. Utrecht, CBO 1993;49-56
26. Van Schaardenburg D, Hazes JMW, De Boer A, Zwiderman AH, Meijers KAE, Breedveld FC. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. *J Rheumatol* 1993;20:45-52
27. Lansink M, De Boer A, Dijkmans BAC, Vandenbroucke JP, Hazes JMW. The onset of rheumatoid arthritis in relation to pregnancy and childbirth. *Clin Exp Rheumatol* 1993;11:171-4
28. Oosterwijk JC, Jansweijer MCE, De Boer A, Rigters-Aris CAE. Klinisch genetische aspecten van kunstmatige donorinseminatie. *Ned. Tijdschr. Gyn/Obstetrie* 1993;106:248-51.
29. De Boer A, Kluit C, Kasper FJ, Kroon JM, Schoemaker HC, Breimer DD, Soons PA, Cohen AF. Interaction study between nifedipine and recombinant tissue-type plasminogen activator. *Br J clin Pharmacol* 1993;36:99-104
30. De Boer A, Kluit C, Gerloff J, Dooijewaard G, Gunzler WA, Beier H, Van der Meer FJM, Cohen AF. Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects. *Thromb Haemostas* 1993;70:320-5.
31. De Boer A. Frequency of adverse drug reactions. *Br J clin Pharmacol* 1993;36:89-90.
32. Bouwes Bavinck JN, De Boer A, Vermeer BJ, Hartevelt MM, Van der Woude FJ, Claas FHJ, Wolterbeek R, Vandenbroucke JP. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. *Br J Dermatol* 1993;129:242-249.
33. De Boer A, Herings RMC. Oral contraceptives without prescription. *Lancet* 1993;342:993.
34. Van der Kuy PHM, Kraaijenga JJ, Meulendijk AJM, De Boer A. Heeft een CARA-patient recht op een ss-blokker? Een meta-analyse van het effect van celiprolol op het geforceerde expiratoire 1-seconde volume. *Pharm Weekbl* 1993;128:1293-1297.
35. Van Hees CLM, De Boer A, Jager MJ, Bleeker JC, Kakebeeke H, Crijns MB, Vandenbroucke JP, Bergman W. Are atypical nevi a risk factor for uveal melanoma? A case control study. *J Invest Dermatol* 1994;103:202-205.
36. Ganesh S, Sier CFM, Griffioen G, Vloedgraven HJM, De Boer A, Welvaart K, Van de Velde CJH, Van Krieken JHJM, Verheijen JH, Lamers CBHW, Verspaget HW. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. *Cancer Res* 1994;54:4065-71.
37. De Boer A. Zidovudine (Retrovir®): vroeg behandelen of niet. *Gebu Prikbord* 1994;28:75-76.
38. Berkel J, Filius PMG, Dik E, De Boer A. Long term health effects of breast augmentation: a review. *Pharmacoepidemiology and drug safety*. 1994;3:265-273.
39. De Boer A, Oosterwijk JC, Rigters-Aris CAE. Determination of a maximum number of artificial insemination by donor children per sperm donor. *Fertil Steril* 1995;63:419-21
40. Herings RMC, De Boer A, Stricker BHCh, Bakker A, Sturmans F. A rapid method to estimate the incidence and prevalence of insulin-dependent diabetes mellitus in children 0-19 years of age. *Pharmacy World and Science* 1995;17:17-9.

41. De Boer A. Farmacologie van laag moleculaire heparines en heparinoiden. In: Medicamenteuze therapie: controversen en nieuwe inzichten. red. JHM Schellens et al. Boerhaave Commissie voor Postacademisch Onderwijs in de Geneeskunde, Rijksuniversiteit Leiden (ISBN 90-6767-258-8) 1995;141-8.
42. De Boer A, Van Griensven JMT. Drug interactions with thrombolytic agents: current experiences. Clin Pharmacokinet 1995;28:315-26
43. Herings RMC, De Boer A, Stricker BHCh, Leufkens HGM, Porsius AJ. ACE-inhibitors and drug induced hypoglycemia. Lancet 1995;345:1195-8
44. De Boer A. Rationeel voorschrijven voor betaalbare geneesmiddelontwikkeling. Oratie Hoogleraar Klinische Farmacologie AF Cohen. Conceptuur 1995;3:6-7
45. Crijns MB, Klaver CCW, De Boer A, Van Hees CLM, Vermeer BJ, Vandenbroucke JP, Bergman W. A comparative study of atypical and melanocytic naevi on the tropical island Curacao and in The Netherlands. Melanoma Research 1995;5:161-7
46. Herings RMC, De Boer A, Stricker BHCh, Leufkens HGM, Porsius AJ. ACE inhibitors and hypoglycaemia. Lancet 1995;346:125-7
47. Herings RMC, De Boer A, Bakker A, Stricker BHCh, Sturmans F. Femurfracturen, vallen en het gebruik van benzodiazepines: dosering belangrijker dan eliminatiehalfwaardetijd. NTvF 1995;1:2-9.
48. Hoekstra AJ, Dik E, De Boer A, Van den Brink G. Stoppen met lithium. NTvF 1995;1:24-28
49. Herings RMC, Stricker BHCh, De Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med 1995;155:1801-1807
50. De Boer A, Leufkens HGM. Vergelijkend geneesmiddelonderzoek. Conceptuur 1995;4/5:24-25
51. De Boer A. Het gebruik van doping onder bodybuilders in Nederland. In de cursusmap van de PAO-cursus "Geneesmiddelen en sport" 14 november 1995
52. De Boer A. Onderzoek naar het gebruik van dopinggeduide middelen bij bodybuilders. In het Programmaboek voor de studiedag 'Doping voor de vorm; een gezondheidsprobleem?' Nationaal Sport Centrum Papendal. 1995:10-12.
53. De Boer A, Leufkens HGM. Vergelijkend geneesmiddelenonderzoek: aanzet tot discussie. Diagnostiek 1995;5:10-11.
54. Herings RMC, De Boer A, Stricker BHCh, Leufkens HGM, Porsius AJ. ACE-remmers vergroten het risico op hypoglycemie bij diabetici. Ned Tijds Genees. 1996;140:432-436.
55. De Boer A, Haren SF, Hartgens F, De Boer D, Porsius AJ. Onderzoek naar het gebruik van prestatie verhogende middelen bij bodybuilders in Nederland. (ISBN 90 800928 5 1). NeCeDo, Rotterdam 1996.
56. Herings RMC, Stricker BHCh, De Boer A, Bakker A, Sturmans F, Stergachis A. Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 1996;49:115-119.
57. Lau HS, Beuning KS, Postma-Lim E, Klein-Beernink L, De Boer A, Porsius AJ. Non-compliance in the elderly: evaluation of risk factors by longitudinal data analysis. Pharm World Sci 1996;18:63-68
58. De Boer A. Vrouwelijke hormonen en het risico op thrombo-embolische ziekten en kanker. In: Vrouwelijke hormonen in de dagelijkse praktijk (ISBN:90-5698-003-3). Schering 1996;pp 35-40
59. Jonker D, Dik E, Willems M, De Boer A. De behandeling van posttraumatische dystrofie: een literatuur overzicht. Pharm Weekbl 1996;131:977-83
60. Leusink JA, Van Dongen HPA, Moll FL, Brons FM, De Boer A. Het gebarsten abdominale aorta-aneurysma: complicaties en mortaliteit bij 309 patienten. Intensive Care Review 1996;11:131-4
61. Klungel OH, Paes AHP, De Boer A, Schut-Meijwes FB, Seidell JC, Bakker A. Gender differences in self-reported antihypertensive drug use in the Netherlands. In: Berg MJ, Francke GN, Rollings MR eds. Proceedings of 55th World Congress of Pharmacy and Pharmaceutical Sciences: Gender-related health issues - International Forum of Women for Pharmacy. Stockholm: American Pharmaceutical Association. 1996:165-7
62. Tissot van Patot HA, Leusink JA, Roodenburg J, De Jongh BM, Lau HS, De Boer A. Selective decontamination of the digestive tract: effect of cessation of routine application at an ICU. Pharm World Sci 18;1996:171-7.
63. De Boer A. Why do we still study and discuss homeopathy. EPSA Newsletter 1996;3:6-7
64. De Boer A, Leufkens HGM. De ontwikkelingsgeneeskundige benadering vanuit de optiek van de farmaco-epidemiologie. Innovator 1996;4:16-17.

65. De Boer A. Epidemiologie van ziekten bij kinderen. *Pharm Weekbl* 1997;132:425-8.
66. Hofste WJ, Linssen CAM, Boezeman EHJF, Hengeveld JS, Leusink JA, De Boer A. Delirium and cognitive disorders after cardiac operations. *International Journal of Clinical Monitoring and Computing* 1997;14:29-36
67. De Boer A. De waarde van pharmacoeconomics voor beslissingen in de farmacotherapie. In: *Pharmacoeconomics*. red. DD Breimer et al. Boerhaave Commissie voor Postacademisch Onderwijs in de Geneeskunde, Rijksuniversiteit Leiden (ISBN 90-6767-358-7) 1997;11-6
68. Van der Werff YD, Van der Houwen HK, Heijmans PJM, Duurkens VAM, Leusink JA, Van Heeswijk HPM, De Boer A. Postpneumectomy pulmonary edema: a retrospective analysis of incidence and possible risk factors. *Chest* 1997;111:1278-84
69. Klungel OH, De Boer A, Paes AHP, Seidell JC, Bakker A. Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. *J Hypertens* 1997;15:591-600
70. Lau HS, De Boer A, Beuning KS, Porsius AJ. Validation of pharmacy records in drug exposure assessment. *J Clin Epidemiol* 1997;50:619-25
71. De Boer A, Oosterwijk JC, Rigters-Aris CAE. Excessive use of a single donor? And inadvertent consanguinity. *Fertil Steril* 1997;67:1181-5
72. De Boer A, Porsius AJ. Why do scientists still study and discuss homeopathy? *Pharm World Sci* 1997;19:176-7
73. De Boer A. Gebruik van prestatieverhogende middelen op sportscholen in Nederland. *Pharm Weekbl* 1997;132:1366-72
74. Linssen CAM, Leusink JA, de Boer A. Algemeen welbevinden van patienten na open-hartchirurgie. *Intensive Care Review* 1997;12:199-203
75. De Boer A, Lau HS, Porsius AJ. Physician-assisted death and pharmacy practice in the Netherlands. *N Engl J Med* 1997;337:1091-2
76. Wesselink RMJ, De Boer A, Morshuis WJ, Leusink JA. Cardio-pulmonary-bypass time has important independent influence on mortality and morbidity. *Eur J Cardiothorac Surg* 1997;11:1141-5
77. Shackleton DP, Westendorp, RGJ, Kasteleijn-Nolst Trenite DGA, De Boer A, Herings RMC. Epileptic medication: a road to determining the number of individuals with seizures. *J Clin Epidemiol* 1997;50:1061-8
78. Crijns MB, Klaver CCW, De Boer A, Van Hees CLM, Vermeer BJ, Vandenbroucke JP, Bergman W. Ultraviolet exposure and the development of banal and atypical naevi: a cross sectional study on Curacao and in The Netherlands. *Melanoma Research* 1997;7:407-16
79. Herings RMC, De Boer A. Promise of clinical genetics in developing new leads in pharmacotherapy: first reflections. *Conceptuur* 1997;14:39
80. Klungel OH, De Boer A, Paes AHP, Seidell JC, Bakker A. Sex-based differences in the pharmacological treatment of hypertension: insights from health services research: Reply. *J Hypertens* 1997;15:1528
81. Klungel OH, Seidell JC, De Boer A. Assessment of control of hypertension in the population. Letter-to-the-editor *J Hypertens* 1998;3:395-6
82. Van Dongen HPA, Leusink JA, Moll FL, Brons FM, De Boer A. Ruptured abdominal aortic aneurysms: Factors influencing post-operative mortality and long term survival. *Eur J Vasc Endovasc Surg.* 1998;15:62-6
83. Klungel OH, De Boer A, Paes AHP, Seidell JC, Bakker A. Sekseverschillen in de farmacologische behandeling van hypertensie. *Pharm Weekbl* 1998;133:872-6
84. Ter Riet G, De Craen AJM, De Boer A, Kessels AGH. Is placebo analgesia mediated by endogenous opioids? A systematic review. *Pain* 1998;76:273-5
85. Kroon C, De Boer A, Kroon JM, Schoemaker HC, Meinders AE, Cohen AF. Comparison of the anticoagulant effect of two low molecular weight heparins (LMWH); dalteparin (FragminR), nadroparin (FraxiparinR), a glycosaminoglycan (heparinoid); danaparoid (OrgaranR) and unfractionated heparin (UH), after subcutaneous and intravenous administration of prophylactic doses in healthy volunteers. Thesis, Leiden pp .....
86. Klungel OH, De Boer A, Paes AHP, Seidell JC, Nagelkerke NJD, Bakker A. Undertreatment of hypertension in a population-based study in the Netherlands. *J Hypertens* 1998;16:1371-8
87. Klungel OH, De Boer A, Paes AHP, Seidell JC, Bakker A. Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. *J Hypertens* 1998;16:1545-53

88. Klungel OH, Seidell JC, De Boer A. Overestimation of the prevalence of hypertension in the population. [Correspondence] *J Hypertension* 1998;16:1702
89. Ter Riet G, De Craen AJM, De Boer A, Kessels AGH. Do endorphins mediate placebo analgesia? A critical commentary on one of the seminal papers. *Forwsch Komplementarmed* 1998;5:12-14
90. De Boer A, Van Dongen HPA, Leusink JA, Moll FL. Ruptured aortic aneurysms -Authors' reply. *Eur J Vasc Endovasc Surg* 1998;16:543
91. Lau HS, De Boer A, Van den Broek IJPM, Porsius AJ. Self-reported drug-related problems in patients admitted to general medical wards. In Disseration 'Drug related problems in the lederly. Studies on occurrence and interventions'. 1998;69-84
92. Lau HS, De Boer A, Soekhlal A, Porsius AJ. Drug-related hospital admissions in patients admitted to general medical wards. In Disseration 'Drug related problems in the lederly. Studies on occurrence and interventions'. 1998;85-105
93. Lau HS, De Boer A, Klerkx MB, Porsius AJ. Effects of two interventions on the pharmacotherapy during and after hospital stay in patients admitted to general medical wards. In Disseration 'Drug related problems in the lederly. Studies on occurrence and interventions'. 1998;107-126
94. De Boer A. Farmacotherapie en 'evidence based medicine'. Problemen bij de interpretatie van geneesmiddelenonderzoek. *Pharm Weekbl* 1999;134:167-71
95. Van Dongen EP, Ter Beek HT, Schepens MA, Morshuis WJ, Langemeijer HJ, De Boer A, Boezeman EH. Within-patient variability of myogenic motor-evoked potentials to multipulse transcranial electrical stimulation during two levels of partial neuromuscular blockade in aortic surgery. *Anesth Analg* 1999;88:22-7
96. Bouvy M, Heerdink R, Klungel OH, De Boer A, Leufkens HGM. Women with angina pectoris receive less antiplatelet treatment than men. *British Journal of General Practice* 1999;49:299-300
97. Van Dongen EP, Ter Beek HT, Schepens MA, Morshuis WJ, De Boer A, Aarts LP, Boezeman EH. Effect of nitrous oxide on myogenic motor potentials evoked by a six pulse train of transcranial stimuli: a possible monitor for aortic surgery. *Br J Anaesth* 1999;82:323-8
98. Conemans JMH, De Boer A, Jonkman JHG, Wemer J, Tamminga W, Wilffert B, Brouwers JRB, Uges DRA, Neef C, Van Vlijmen B, Beijnen JH, Touw DJ, Hermens WAJJ, Duchateau AMJA. Is genotypering nuttig als instrument bij de therapie van geneesmiddelen. *Pharm Weekbl* 1999;134:832-7
99. Klungel OH, Stricker BhC, Paes AHP, Seidell JC, Bakker A, Voko Z, Breteler MMB, De Boer A. Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. *Stroke* 1999;30:1312-8
100. Van Dongen EP, Ter Beek HT, Schepens MA, Morshuis WJ, Leusink JA, De Boer A, Boezeman EH. Within patient variability of lower extremity muscle responses to transcranial electrical stimulation with pulse trains in aortic surgery. *Clin Neurophysiol* 1999;110:1144-8.
101. Van Dongen EP, Ter Beek HT, Schepens MA, Morshuis WJ, Haas FJ, De Boer A, Boezeman EH, Aarts LP. The relationship between evoked potential and measurements of S-100 protein in cerebrospinal fluid during and after thoracoabdominal aortic aneurysm surgery. *Journal of Vascular Surgery* 1999;30:293-300
102. Klungel OH, De Boer A, Paes AHP, Seidell JC, Bakker A. Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. *Pharm World Sci* 1999;21:217-20.
103. Klungel OH, De Boer A, Paes AHP, Seidell JC, Bakker A. Cardiovascular diseases and risk factors in a population-based in the Netherlands. Agreement between questionnaire information and medical records. *Neth J Med* 1999;55:177-83.
104. Klungel OH, De Boer A. 'Dear Colleague'. 1999;2:4-5.
105. Van den Vijver DAMC, De Boer A. Effect van selegiline op mortaliteit in patienten met de ziekte van Parkinson. *Pharm Weekb* 1999;134:1602-3
106. Teeuwisse A, Porsius AJ, De Boer A. Kwaliteit van behandeling van patienten met hypercholesterolomie. *Pharm Weekbl* 1999;134:1680-3
107. De Boer A, Peterse EEM, Teeuwisse AK, Porsius AJ. De medicamenteuze behandeling van hyperlipidemie. *Pharm Weekbl* 1999;134:1167-71
108. Klungel OH, Seidell JC, Paes AHP, De Boer A. Onderbehandeling van hypertensie: Voorkomen, gevolgen en determinanten. *Cardiologie* 1999;6:556-60
109. Klungel OH, De Boer A, Paes AHP, Seidell JC, Nagelkerke NJD, Bakker A. Influence of correction for within-person variability in blood pressure on the prevalence, awareness, treatment,

- and control of hypertension. *Am J Hypertens* 2000;13:88-91
110. Teeuwisse A, Klungel OH, Porsius AJ, De Boer A. Cholesterolverlagers en doelmatigheid. *Pharm Weekbl* 2000;135:106
111. Klungel OH, Kaplan RC, Heckbert SR, Smith NL, Lemaitre RN, Longstreth WT, Leufkens HGM, De Boer A, Psaty BM. Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients. *Stroke* 2000;31:420-4
112. Klungel OH, De Boer A, Leufkens HGM. Effectiviteit van geneesmiddelen in de dagelijkse praktijk. *Conceptuur* 2000;22:10-1
113. Maitland-van der Zee AH, Klungel OH, Leufkens HGM, De Boer A. Geneesmiddeltherapie en het genotype van de patient. *Pharm Weekbl* 2000;135:378-9
114. Klungel OH, De Boer A, Paes AHP, Herings RMC, Seidell JC, Bakker A. Influence of question stucture on the recall of self-reported drug use. *J Clin Epidemiol* 2000;53:273-7
115. Rijntjes V, Aadmi L, Fietje EH, Dankert-Roelse JE, De Boer A. Inventarisatie van de behandeling van Primaire Ciliaire Dyskinesie. (ISBN 90 74772 40 4). Wetenschapswinkel Geneesmiddelen, Utrecht, 2000
116. Lau HS, Riezebos J, Abas V, Porsius AJ, De Boer A. A nation-wide study on the practice of euthanasia and physician-assisted suicide in community and hospital pharmacies in the Netherlands. *Pharm World Sci* 2000;22:3-9
117. Klungel OH, Seidell JC, De Boer A. Overestimation of the number of individuals with hypertension who are eligible for treatment according to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. [Correspondence] *Arch Intern Med* 2000;160:1540
- 118 Klungel OH, Leufkens HGM, De Boer A. Estimation of the Absolute Benefit of Drug Treatment of Hypertension [electronic letter]. *Hypertension* 2000; [http://hyper.ahajournals.org/cgi/eletters?lookup=by\\_date&days=30#35/2/539/EL1](http://hyper.ahajournals.org/cgi/eletters?lookup=by_date&days=30#35/2/539/EL1)
119. Lau HS, Florax C, Porsius AJ, De Boer A. The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. *Br J Clin Pharmacol* 2000;49:597-603
120. Klungel OH, Paes AHP, Seidell JC, Kuyvenhoven MM, De Boer A. Sekseverschillen bij de medicamenteuze behandeling van hypertensie door de huisarts. *Huisarts & Wetenschap* 2000;43:303-5
121. Klungel OH, Stricker BhC, Breteler MMB, Seidell JC, De Boer A. Onderbehandeling van hypertensie en het risico op beroerte bij de oudste ouderen. *Tijdschr Gerontol Geriatr* 2000;31:119-22
122. Van Eijk MEC, Bahri P, Dekker G, Herings RMC, Porsius AJ, Avorn J, De Boer A. The use of prevalence and incidence measures to describe age related prescribing of antidepressants with and without anticholinergic effects. *J Clin Epidemiol* 2000;53:645-51
123. Vonk R, Conemans JMH, Hermens WAJJ, Bernsen J, Brouwer M, De Boer A. Is kennis van het cytochrom genotype CYP2D6 en CYP2C19 van belang voor de behandeling van de psychiatrische patient. Verslag van een pilotstudie en de opzet van een vervolgstudie. *De Ark* 2000;9:14-7
124. Van Dongen EP, Ter Beek HT, Aarts LP, Schepens MA, Morshuis WJ, Benning FJ, De Boer A, Boezeman EH. The effect of two low-dose propofol infusions on the relationship between six-pulse transcranial electrical stimulation and the evoked lower extremity muscle response. *Acta Anaesthesiol Scand.* 2000;44:799-803
125. Klungel OH, Paes AHP, De Boer A, Kuyvenhoven MM, Seidell JC, Bakker A. Sex differences in the medicaton choice for hypertension in general practice. A study with written case simulations. *Pharm World Sci* 2000;22:140-6
126. De Boer A, Klungel OH, Leufkens HGM. Pharmacogenetics. *Farmakopij* 2000;10(142):2-3
127. Klungel OH, De Boer A, Paes AHP, Nagelkerke NJD, Seidell JC, Bakker A. Estimating the prevalence of hypertension corrected for the effect of within-person variability in blood pressure. *J Clin Epidemiol* 2000;53:1158-63
128. Maitland -van der Zee AH, De Boer A, Leufkens HGM. The interface between pharmacoepidemiology and pharmacogenetics. *Eur J Pharmacol* 2000;410:121-30
129. Van de Vijver DAMC, Roos RAC, Jansen PAF, Porsius AJ, de Boer A. Start of antidepressant drugs in Parkinson's disease: association with the disease and its course. *Int J Ger Psychopharmacol* 2000;2:148-152
130. Klungel OH, Heckbert SR, Longstreth WT, Furberg CD, Kaplan RC, Smith NL, Lemaitre RN, Leufkens HGM, De Boer A, Psaty BM. Antihypertensive drug therapies and the risk of ischemic stroke. *Arch Intern Med* 2001;161:37-43

131. Van Eijk MEC, Porsius AJ, Avorn J, De Boer A. Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus individual academic detailing. *BMJ* 2001;322:654-7
132. Klungel OH, Stricker BhC, Breteler MMB, Seidell JC, Psaty BM, De Boer A. Is drug treatment of hypertension in clinical practice as effective as in randomized controlled trials with regard to the reduction of the incidence of stroke? *Epidemiology* 2001;11:339-44
133. Mantel-Teeuwisse AK, Kloosterman JME, Maitland-van der Zee AH, Klungel OH, Porsius AJ, De Boer A. Drug-induced lipid changes: A review of the unintended effects of some commonly used drugs on serum lipid levels. *Drug Safety* 2001;24:443-56
134. Van Vliet J, Leusink JA, De Jongh BM, De Boer A. A comparison between two types of central venous catheters in the prevention of catheter-related infections: the importance of performing all the relevant cultures. *Clinical Investigative Care* 2001;12:135-140
135. Schillevoort I, De Boer A, Herings RMC, Roos RAC, Jansen PAF, Leufkens HGM. Antipsychotic induced extrapyramidal syndromes: risperidone compared with low and high potency conventional antipsychotic drugs. *Eur J Clin Pharmacol* 2001;57:327-31
136. Van de Vijver DAMC, Stricker BHCh, Breteler MMB, Roos RAC, Porsius AJ, De Boer A. Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease. *Pharm World Sci* 2001;23:148-52
137. Klungel OH, Leufkens HGM, De Boer A, Longstreth WT, Kaplan RC, Smith NL, Psaty BM. 'Differences Between Primary vs Secondary Prevention Trials Regarding the Stroke Protective Effect of Antihypertensive Drugs.' In reply. *Arch Intern Med* 2001;161:2152-3
138. Mantel-Teeuwisse AK, Klungel OH, Verschuren WMM, Porsius AJ, De Boer A. Comparison of different methods to estimate prevalence of drug use by using pharmacy records. *J Clin Epidemiol* 2001;54(11):1181-6
139. Maitland-van der Zee AH, Klungel OH, Kloosterman JM, Seidell JC, Leufkens HGM, De Boer A. The association between antihypertensive drug therapies and plasma lipid levels in the general population. *J Hum Hypertens.* 2001;15:701-5.
140. Van Eijk MEC, Krist LFG, Avorn J, Porsius AJ, De Boer A. Do the research goal and databases match? A checklist for a systematic approach. *Health Policy* 2001;58:263-274
141. Van Dongen EP, Schepens MA, Morshuis WJ, Ter Beek HT, Aarts LP, De Boer A, Boezeman EH. Thoracic and thoracoabdominal aortic aneurysm repair: Use of evoked potential monitoring in 118 patients. *J Vasc Surg* 2001;34:1035-40
142. Schillevoort I, De Boer A, Herings RMC, Roos RAC, Jansen PAF, Leufkens HGM. Risk of extrapyramidal syndromes with haloperidol, risperidone or olanzapine. *Ann Pharmacother* 2001;35:1517-22
143. Mantel-Teeuwisse AK, Klungel OH, De Boer A. Lipid Abnormalities Induced by Novel Antipsychotic Drugs. *Reply Drug Saf.* 2001;24:1017-1018
144. Van den Vijver DAMC, Roos RAC, Jansen PAF, Porsius AJ, De Boer A. Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records. *Pharmacoepidemiology and Drug Safety* 2001;10:549-54
145. Van den Vijver DAMC, Roos RAC, Jansen PAF, Porsius AJ, De Boer A. Influence of benzodiazepines on antiparkinsonian drug treatment in levodopa users. *Acta Neurol Scand* 2002;105:8-12
146. Bosman AAP, Maitland-van der Zee AH, Klungel OH, Leufkens HGM, De Boer A. Cholesterol als risicofactor voor het krijgen van een beroerte. Laveren tussen hoog en laag ? *Pharmaceutisch Weekblad* 2002;137:329-332
147. De Maat MMR, Frankfort SV, Mathot RAA, Mulder JW, Meenhorst PL, Van Gorp ECM, Hoetelmans RMW, De Boer A, Beijnen JH. Discrepancies between medical and pharmacy records for patients on Anti-HIV drugs. *Ann Pharmacother* 2002;36:410-5
148. Schillevoort I, De Boer A, Van der Weide J, Roos RAC, Jansen PAF, Leufkens HGM. Antipsychotic-induced extrapyramidal syndromes and CYP2D6 genotype: a case-control study. *Pharmacogenetics* 2002;12:235-40
149. Van den Vijver DAMC, Roos RAC, Jansen PAF, Porsius AJ, De Boer A. Antipsychotics and Parkinson's disease: association with disease and drug choice during the first five years of antiparkinsonian drug treatment. *Eur J Clin Pharmacol* 2002;58:157-61
150. Mantel-Teeuwisse AK, Klungel OH, Verschuren WMM, Porsius AJ, De Boer A. Time trends in lipid lowering drugs use in the Netherlands. Has the backlog of candidates for



- treatment been eliminated? Br J Clin Pharmacol 2002;53:379-85
151. Klungel OH, Heckbert SR, Longstreth WT, De Boer A, Leufkens HGM, Sullivan SD, Fishman PA, Veenstra DL, Psaty BM. Lipid-lowering drug use and cardiovascular events after myocardial infarction. Ann Pharmacother 2002;36:751-7
152. Van de Vijver DAMC, Hugtenburg RMC, De Boer A. Epidemiologie van ziekten en gebruik van receptgeneesmiddelen bij kinderen. Pharmaceutisch Weekblad 2002;137:639-43
153. Lau HS, Muller JM, Eskes PF, Lenters E, Van der Westerlaken MML, De Boer A. Perinatale infecties: voorkomen en behandeling. Pharmaceutisch Weekblad 2002;137:746-7.
154. Maitland-van der Zee AH, Klungel OH, Stricker BHCh, Kastelein JJ, Leufkens HGM, De Boer A. Genetic polymorphisms: importance for response to cholesterol-lowering therapy. Atherosclerosis 2002;163:213-22
155. Schillevoort I, Van Puijenbroek EP, De Boer A, Roos RAC, Jansen PAF, Leufkens HGM. Extrapyrimal syndromes associated with selective serotonin reuptake inhibitors - a case control study using spontaneous reports. Int Clin Psychopharmacol 2002;17:75-9
156. Stolk LML, Degraeuwe PLJ, Nieman FHM, De Wolf MC, De Boer A. Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin neonates. Ther Drug Monit 2002;24:527-31
157. Schillevoort I, De Boer A, Roos RAC, Jansen PAF, Leufkens HGM. Risk of extrapyramidal syndromes with haloperidol, risperidone or olanzapine. Authors reply. Ann Pharmacother. 2002;36:1293
158. Jansen MMPM, Heymer F, Leusink JA, De Boer A. The quality of nutrition at an intensive care unit. Nutrition Research 2002;22:411-22
159. Van Eijk MEC, Belitser SV, Porsius AJ, De Boer A. Evaluation of patient outcomes in an area where prescribing of anticholinergic antidepressants was influenced by academic detailing. Pharm World Sci 2002;24:144-8
160. Van den Vijver DAMC, Roos RAC, Jansen PAF, Porsius AJ, De Boer A. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 2002;54:168-70
161. Mantel-Teeuwisse AK, Klungel OH, Herings RMC, Van Puijenbroek E, Porsius AJ, De Boer A. Myopathy due to statin/fibrate use in the Netherlands. Ann Pharmacother 2002;36:1957-60
162. Maitland -van der Zee AH, Stricker BHCh, Klungel OH, Kastelein JJP, Leufkens HGM, Van Duijn CM, Hofman A, De Boer A. The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. Pharmacogenetics. 2002;12:647-653.
163. Maitland-van der Zee AH, De Boer A, Leufkens HGM. Pharmacogenetics and the role of the pharmacist. Journal of Research in Pharmaceutical Economics. 2001;11:143-150.
164. Van der Elst ME, Cisneros-Gonzalez N, De Blaey CJ, Buurma H, De Boer A. Oral antithrombotic use among myocardial infarction patients. Ann Pharmacother 2003;37:143-6
165. De Boer A. Klassensubstitutie van geneesmiddelen. In: Medicamenteuze therapie. red. JHM Schellens, P. Vermeij, A.E. Meinders. Boerhaave Commissie voor Postacademisch Onderwijs in de Geneeskunde, Rijksuniversiteit Leiden (ISBN 90-6767-518-0) 2003;171-7
166. De Maat MMR, Post TM, Jonker DM, Mulder JW, Meenhorst PL, Van Gorp ECM, Koks CHW, De Boer A, Beijnen JH. Pharmacotherapy of hospitalized HIV-infected patients in a general hospital during 1990, 1997 and 2001. Clin Drug Invest 2003;23:45-53
167. Wirts JW, Duyn AE, Geraerts SD, Preijer E, Van Diemen-Steenvoorde JA, Van Leeuwen JH, Haas FJ, Gerritsen WB, De Boer A, Leusink JA. S100 protein content of umbilical cord blood in healthy newborns in relation to mode of delivery. Arch Dis Child Fetal Neonatal Ed. 2003;88:67-9.
168. Maitland-van der Zee, De Boer A. Farmacogenetica: geneesmiddelen therapie aangepast aan het genotype van de patient. Geneesmiddelenbulletin 2003; 37:25-30
169. Maitland-van der Zee AH, Stricker BHCh, Klungel OH, Mantel-Teeuwisse AK, Kastelein JJP, Hofman A, Leufkens HGM, Van Broeckhoven C, Van Duijn CM, De Boer A. Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics 2003;13:219-23
170. Mantel-Teeuwisse AK, Verschuren WMM, Klungel OH, Kromhout D, Lindemans AD, Avorn J, Porsius AJ, De Boer A. Undertreatment of hypercholesterolemia: a population-based study. Br J Clin Pharmacol 2003;55:389-97
171. Maitland-van der Zee AH, Klungel OH, Stricker BHCh, Van der Kuip DAM, Witteman JCM,

- Hofman A, Leufkens HGM, De Boer A. Repeated nitrate prescriptions as a potential marker for angina pectoris: a comparison with medical information from The Rotterdam Study. *Pharm World Sci* 2003;25:70-2
172. Tamminga WJ, Wemer J, Oosterhuis B, De Boer A, Vrankx S, Drenth BFH, De Zeeuw RA, De Leij LFMH, Jonkman JHG. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalized psychiatric patients: a retrospective study. *Eur J Clin Pharmacol* 2003;59:57-64
173. Ramnath AHN, Naber HR, de Boer A, Leusink JA. No benefit of intraoperative whole blood sequestration and autotransfusion during coronary artery bypass grafting: results of a randomized clinical trial. *J Thorac Cardiovasc Surg* 2003;125:1432-7
174. De Boer A. Waarom is het farmaciecurriculum ook alweer totaal vernieuwd? Up to date; 2003;15:18-20
175. Van der Elst ME, Buurma H, Bouvy ML, De Boer A. Drug therapy for prevention of recurrent myocardial infarction. *Ann Pharmacother* 2003;37:1465-77
176. Klungel OH, Mantel-Teeuwisse AK, De Boer A. Medicamenteuze behandeling van hypertensie en hypercholesterolemie. *Pharmaceutisch Weekblad* 2003;138:1383-9
177. De Boer A. Farmaceutische opleidingen Universiteit Utrecht. Keuze tussen basisapotheker en farmaceutisch onderzoeker. *Conceptuur*. 2003;37:18-20.
- 178 Maitland-van der Zee AH, Klungel OH, Stricker BHCh, Veenstra DL, Kastelein JJP, Hofman A, Witteman JCM, Leufkens HGM, Van Duijn CM, De Boer A. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting -hydroxy--methylglutaryl coenzyme A reductase inhibitor therapy in men. *Pharmacogenetics* 2004;14:53-60.
- 179 Mantel-Teeuwisse AK, Klungel OH, Egberts ACG, Verschuren WMM, Porsius AJ, De Boer A. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin. *Drug Saf* 2004;27:63-70
- 180 Maitland-Van Der Zee AH, Klungel OH, Stricker BH, Verschuren WM, Witteman JC, Stijnen T, Hofman A, Breteler MM, Leufkens HG, De Boer A. Comparison of two methodologies to analyze exposure to statins in an observational study on effectiveness. *J Clin Epidemiol*. 2004;57:237-42.
181. Schalekamp T, Van Geest-Daalderop JHH, De Vries-Goldschmeding H, Conemans J, Bernesen MJ, De Boer A. Acenocoumarol stabilization is delayed in CYP2C9\*3 carriers. *Clin Pharmacol Ther* 2004;75:294-402
182. De Maat MM, De Boer A, Koks CH, Mulder JW, Meenhorst PL, Van Gorp EC, Mairuhu AT, Huitema AD, Beijnen JH. Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. *J Clin Pharm Ther* 2004;29:121-30
183. Schelleman H, Klungel OH, Kromhout D, De Boer A, Stricker BHCh, Verschuren WMM. Prevalence and determinants of undertreatment of hypertension in the Netherlands. *J Hum Hypertens* 2004;18:317-24
- 184 Maitland-van der Zee AH, Klungel OH, De Boer A. Genetic Polymorphisms and Responses to HMG-CoA Reductase Inhibitors. Chapter In: "Cardiovascular Genomics": Gene mining for pharmacogenomics and gene therapy. Editors Raizada MK, Paton JFR, Katovich MJ, Kasparov S. The Humana Press Inc. January 2005, ISBN:1-59259-883-8
185. Maitland -van der Zee AH, Stricker BHCh, Klungel OH, Kastelein JJP, Leufkens HGM, Van Duijn CM, Witteman JCM, Hofman A, De Boer A. Effectiveness of HMG-Co reductase inhibitors is modified by the ACE insertion deletion polymorphsim. *Atherosclerosis* 2004;175:377-9
186. Van Wijk BLG, Klungel OH, Heerdink ER, De Boer A. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. *J Hypertens* 2004;22:1831-7
187. Schelleman H, Stricker BHCh, De Boer A, Kroon AA, Verschuren WMM, Van Duijn CM, Psaty BM, Klungel OH. Drug-Gene Interactions between Genetic Polymorphisms and Antihypertensive Therapy. *Drugs* 2004;64:1801-16.
188. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, De Boer A, Herings RMC. Long term persistence with statin treatment in daily medical practice. *Heart* 2004;90:1065-6
189. Mantel-Teeuwisse AK, Verschuren WMM, Klungel OH, De Boer A, Kromhout D. Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands. *Br J Clin Pharmacol*. 2004;58:310-6.
190. Van Eijk MEC, Paes AHP, Porsius AJ, Avorn J, De Boer A. Pre-randomization decisions and group stratification in a randomized controlled trial to improve prescribing. *Pharm World Sci* 2004;26:227-31

191. Van den Vijver DAMC, Roos RAC, Jansen PAF, Porsius AJ, De Boer A. Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa. *Pharm World Sci* 2004;26:277-81
192. Maitland-vander Zee AH, Klungel OH, De Boer A. Pharmacogenetics in health-care practice. *Pharm World Sci* 2004;26:253-5
193. Florentinus SR, Heerdink ER, Klungel OH, De Boer A. Should rosuvastatin be withdrawn from the market? *Lancet* 2004;364:1577.
194. Schalekamp T, Oosterhof M, Van Meegen E, Van der Meer FJM, Conemans J, Hermans M, Meerman I, De Boer A. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. *Clin Pharmacol Ther* 2004;76:409-17
195. Klungel OH, Martens EP, Psaty BM, Grobbee DE, Sullivan SD, Stricker BHCh, Leufkens HGM, De Boer A. Methods to assess intended effects of drug treatment in observational studies are reviewed. *J Clin Epidemiol* 2004;57:1223-31
196. Schelleman H, Klungel OH, Van Duijn CM, Wittelman JCM, Hofman A, De Boer A, Stricker BHCh. Insertion/deletion polymorphism of the ACE gene and adherence to ACE inhibitors. *Br J Clin Pharmacol* 2005;59:483-5
197. Vader CI, Grouls RJE, Korsten HHM, Ackerman EW, Schonberger JPAM, De Boer A, Leufkens HGM. Boezemfibrilleren na bypassoperatie. *Pharm Weekbl* 2005;11:375-8.
198. Schalekamp T, De Boer A. Reply on "Effects of CYP2C9 polymorphism on phenprocoumon anticoagulation status. *Clin Pharmacol Ther* 2005;april:336
199. Van Wijk BLG, Klungel OH, Heerdink ER, De Boer A. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. *Ann Pharmacother* 2005;39:319-28.
200. Florentinus SR, Heerdink ER, De Boer A, Van Dijk L, Leufkens HGM. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. *Pharmacoepidemiology and Drug safety* 2005;14:437-41
201. De Boer A. The rise and fall of the COX-2-inhibitors. *Up to Date* 2005;17:9-13
202. Mantel-Teeuwisse AK, Klungel OH, Schalekamp S, Verschuren WMM, Porsius AJ, De Boer A. Suboptimal choices and dosing of statins at start of therapy. *Br J Clin Pharmacol* 2005;60:83-9
203. Hommerson P, Nedeljkovic SI, Klungel OH, De Boer A, Ostojic MC, Grujic MZ, Vojvodic NM, Bloemberg BP, Kromhout D. Cardiovascular drug use and differences in the incidence of cardiovascular mortality in elderly Serbian men. *Pharm World Sci.* 2005;27:124-8.
204. Gumbs PD, Verschuren WMM, Mantel-Teeuwisse AK, De Boer A, Klungel OH. Medicamenteuze behandeling van hypercholesterolemie kosteneffectief. *Pharm Weekbl* 2005;32:982-3
205. Wu HL, Nijssen LE, Van der Salm A, Denee TR, De Boer A, Klungel OH. Statines bij acuut coronair syndroom. *Pharm Weekbl* 2005;32:995-7
206. Van Wijk BLG, Klungel OH, Heerdink ER, De Boer A. Rate and determinants of 10-years persistence with antihypertensive drugs. *J Hypertens* 2005;23:2101-7
207. Schillevoort I, Herings RMC, Hugenholtz GWK, De Boer A, Nolen WA, Roos RAC, Leufkens HGM. Antipsychotic induced extrapyramidal syndromes in psychiatric practice: a case-control study. *Pharm World Sci* 2005;27:285-9
208. De Boer A. Hoe nu verder met de COX-2-remmers? *Geneesmiddelenbulletin* 2005;39: 121-9 Frankfort
209. SV, Appels BA, De Boer A, Tulner LR, Van Campen JPCM, Koks CHW, Beijnen JH. Discontinuation of rivastigmine in routine clinical practice. *Int J geriatr Psychiatry* 2005;20:1167-71
210. Van der Elst ME, Bouvy ML, De Blaey CJ, De Boer A. Preventive Drug Use in Patients with a History of Nonfatal Myocardial Infarction During 12-Year Follow-Up in The Netherlands: A Retrospective Analysis. *Clinical Therapeutics* 2005;27:1806-14.
211. Van Wijk BLG, Klungel OH, Heerdink ER, De Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? *Ann Pharmacother* 2006;40:15-20
212. Van Wijk BLG, Klungel OH, Heerdink ER, De Boer A. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. *J Clin Epidemiol.* 2006;59:11-7
213. Schelleman H, Stricker BHCh, Verschuren WMM, De Boer A, Kroon AA, De Leeuw PW, Kromhout D, Klungel OH. Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. *Pharmacogenomics J* 2006;6:22-6

214. Schelleman H, Klungel OH, Van Duin CM, Witteman JC, Hofman A, De Boer A, Stricker BHCh. Drug-gene interaction between the insertion/deletion polymorphism of the Angiotensin-converting enzyme gene and antihypertensive therapy. *Ann Pharmacother.* 2006;40:212-8
215. Van der Elst ME, Bouvy ML, De Blaey CJ, De Boer A. Improving pharmacotherapy after myocardial infarction by group academic detailing using feedback data on a patient level. *Pharmacotherapy.* 2006;26:254-9.
216. Schelleman H, Klungel OH, Van Duin CM, Witteman JC, Hofman A, De Boer A, Stricker BHCh. The influence of alpha-adducin G460W polymorphism and angiotensin M235T polymorphism on antihypertensive medication and blood pressure. *European Journal of Human Genetics* 2006;14:860-6.
217. Van Wijk BLG, Klungel OH, Heerdink ER, De Boer A. Initial non-compliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy. *Pharmacoepidemiol Drug Saf.* 2006;15:587-93.
218. Martens EP, Pestman WR, De Boer A, Belitser SV, Klungel OH. Instrumental variables. Applications and limitations. *Epidemiology* 2006;17:260-7
219. De Boer A. Pharmacogenomics: methods and protocol. Book Reviews. *Annals of Pharmacotherapy.* 2006;40:1001-2.
220. Mantel-Teeuwisse AK, Klungel OH, Hofman A, Verschuren WMM, Trienekens PH, Porsius AJ, Stricker BHCh, De Boer A. Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999), *Br J Clin Pharmacol* 2006;61:592-600
221. Schalekamp T, Boink GJ, Visser LE, Stricker BH, De Boer A, Klungel OH. CYP2C9 genotyping in acenocoumarol treatment: Is it a cost-effective addition to international normalized ratio monitoring? *Clin Pharmacol Ther* 2006;79:511-20
222. Bijl D, De Boer A. Geven COX-2-remmers een betere verlichting van artroseklachten dan paracetamol. *Reumatologen Vademecum* 2006;9:1-3
223. Frankfort SV, Appels BA, De Boer A, Tulner LR, Van Campen JPMC, Koks CHW, Beijnen JH. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting. *Int J Clin Pract* 2006;60:646-54
224. Schalekamp T, Brasse BP, Roijers JF, Chahid Y, Van Geest-Daalderop JH, De Vries-Goldschmeding H, de Boer A. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. *Clin Pharmacol Ther.* 2006;80:13-22.
225. Schalekamp T, Smit C, Van Geest-Daalderop JH, De Vries-Goldschmeding H, de Boer A. Discrepancies between medication records of anticoagulation clinics and pharmacy records. *Pharmacoepidemiol Drug Saf.* 2006;15:823-8.
226. Maitland-van der Zee AH, Jukema JW, Zwinderman AH, Hallman DM, De Boer A, Kastelein JJ, De Knijff P. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). *Acta Cardiol.* 2006 61:327-31.
227. Van Wijk BLG, Klungel OH, Heerdink ER, De Boer A. A Comparison of Two Multiple-Characteristic Decision-Making Models for the Comparison of Antihypertensive Drug Classes: Simple Additive Weighting (SAW) and Technique for Order Preference by Similarity to an Ideal Solution (TOPSIS). *Am J Cardiovasc Drugs.* 2006;6:251-8.
228. Gumbs PD, Verschuren WMM, Mantel-Teeuwisse AK, De Wit AG, Hofman A, Trienekens PH, Stricker BHCh, De Boer A, Klungel OH. Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: The Rotterdam Study. *Drugs Aging* 2006;23:733-41.
229. Frankfort SV, Appels BA, De Boer A, Tulner LR, Van Campen JPMC, Koks CHW, Beijnen JH, Schamndt BA. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. *Pharmacoepidemiol Drug Saf* 2006;16:545-51.
230. Schelleman H, Klungel OH, Witteman JC, Breteler MM, Hofman A, Van Duin CM, De Boer A, Stricker BHCh. Diuretic-gene interaction and the risk of myocardial infarction and stroke. *Pharmacogenomics J.* 2007;7:346-52
231. Schalekamp T, Brasse BP, Roijers JF, Van Meegen E, Van der Meer FJ, Van Wijk EM, Egberts AC, De Boer A. VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement. *Clin Pharmacol Ther.* 2007;81:185-93

232. Van Wijk BL, Avorn J, Solomon DH, Klungel OH, Heerdink ER, De Boer A, Brookhart AM. Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study. *J Hypertens*. 2007;25:689-697.
233. Schelleman H, Klungel OH, Witteman JCM, Hofman A, Van Duin CM, De Boer A, Stricker BHCh. Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or beta-blockers and the risk of atherosclerosis. *Br J Clin Pharmacol* 2007; 64:57-66
234. Schelleman H, Klungel OH, Witteman JCM, Breteler MMB, Yazdanpanah M, Danser AHJ, Hofman A, Van Duin CM, De Boer A, Stricker BHCh. Angiotensin M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. *Eur J Hum Genet* 2007;15:478-84
235. Schalekamp T, Van Geest-Daalderop JH, Kramer MH, Van Holten-Verzantvoort HT, De Boer A. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. *Eur J Clin Pharmacol*. 2007;63:335-43.
236. Gumbs PD, Verschuren WMM, Mantel-Teeuwisse AK, De Wit AG, De Boer A, Klungel OH. Economic Evaluations of Cholesterol-Lowering Drugs : A Critical and Systematic Review. *Pharmacoeconomics*. 2007;25:187-99.
237. Frankfort SV, Appels BA, De Boer A, Tulner LR, Van Campen JPCM, Koks CHW, Beijnen JH, Schmand BA. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. *Pharmacoepidemiol Drug Saf* 2007;16:545-551
238. Van der Elst ME, Bouvy ML, De Blaey CJ, De Boer A. Effect of drug combinations on admissions for recurrent myocardial infarction. *Heart* 2007;93:1226-30
239. Gumbs PD, Verschuren WMM, Souverein PC, Mantel-Teeuwisse AK, De Wit GA, De Boer A, Klungel OH. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. *Br J Clin Pharmacol* 2007; Economic Evaluations of Cholesterol-Lowering Drugs : A Critical and Systematic Review. *Pharmacoeconomics*. 2007;25:187-99.
240. Bozkurt O, De Boer A, Grobbee DE, Heerdink ER, Burger H, Klungel OH. Pharmacogenetics of glucose-lowering drug treatment. A systematic review. *Mol Diag Ther* 2007;11:291-302
241. Martens EP, De Boer A, Pestman WR, Belitser SV, Stricker BH, Klungel OH. Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods. *Pharmacoepidemiol Drug Saf*. 2008;17:1-8
242. Schalekamp T, Klungel OH, Souverein PC, De Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. *Arch Intern Med*. 2008;168:180-5.
243. Ahlers SJ, Van Gullik L, Van der Veen AM, Van Dongen HP, Bruins P, Belitser SV, De Boer A, Tibboel D, Knibbe CA. Comparison of different pain scoring systems in critically ill patients in a general ICU. *Crit Care* 2008;12:R15
244. Schellens JHM, Grouls R, Guchelaar HJ, Touw DJ, Rongen GA, De Boer A, Van Bortel LM. The Dutch model for clinical pharmacology: collaboration between physician- and pharmacist-clinical pharmacologists. *Br J Clin Pharmacol* 2008;66:146-9
245. Schelleman H, Klungel OH, Witteman JCM, Breteler MMB, Hofman A, Van Duin CM, De Boer A, Stricker BHCh. Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. *Pharmacogenomics J* 2008;6:22-6
246. Otte WM, Van der Maas F, De Boer A. Comparison of knowledge and accessibility to information sources of HIV/AIDS between blind and sighted populations in Nigeria. *AIDS Care* 2008;20:1093-7
247. Martens EP, Pestman WR, De Boer A, Belitser SV, Klungel OH. Systematic differences in treatment effect estimates between propensity score methods and logistic regression. *Int J Epidemiol* 2008;37:1142-7
248. Swen JJ, Wilting I, De Goede AL, Grandia L, Mulder H, Touw DJ, De Boer A, Conemans JMH, Egberts ACG, Klungel OH, Koopmans R, Ven der Weide J, Wilffert B, Guchelaar HJ, Deneer VHM. Pharmacogenetics: from bench to byte. *Clin Pharmacol Ther* 2008;83:781-8.
249. Peters BJM, Maitland-van der Zee AH, Stricker BHCh, Van Wieren-de Wijer BM, De Boer A, Kroon AA, De Leeuw PW, Schiffers P, Janssen RG, Van Duijn CM, Klungel OH. Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. *Pharmacogenet Genomics*. 2008;18:631-6

250. Bozkurt O, Verschuren WMM, Van Wieren-de Wijer BM, Knol MJ, De Boer A, Grobbee DE, Geerlings MI, Heerdink ER, Klungel OH. Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives. *J Hum Hypertens*. 2008;22:774-80
251. Schalekamp T, Maitland-van der Zee AH, De Boer A. Pharmacogenomics of coumarin anticoagulants: Are we underestimating the role of CYP2C9? *Thromb Haemost*. 2008;100:175-6.
252. Schalekamp T, Klungel OH, Souverein PC, De Boer A. Effect of oral antiplatelet agents on major bleeding in users of coumarins. *Thromb Haemost* 2008;100:1076-83.
253. Peters BJM, Klungel OH, De Boer A, Stricker BHC, Maitland-van der Zee AH. Pharmacogenetics of cardiovascular risk therapy. *Clin Cases Miner Bone Metab* 2009;6:55-65
254. Brasse BP, Roijers JFM, Chahid Y, Van Geest-Daalderop JHH, De Vries-Goldschmeding H, Van Wijk EM, De Boer A, Egberts AC, Schalekamp-T. Invloed van genotypen VKORC1 en CYP2C9 op acenocoumarolpodosisbehoefte. *Pharm Weekbl* 2009;3:4-8.
255. Van Wijk BLG, De Boer A. Generieke geneesmiddelen substitutie en therapietrouw. *Pharm Weekbl* 2009;3:2-3
256. Van Wieren-de Weier BMA, Maitland-van der Zee AH, De Boer A, Kroon AA, De Leeuw PW, Schiffers P, Jansen RGJH, Psaty BM, Van Duijn CM, Stricker BHC, Klungel OH. Interactions between the Gly460Trp -adducin gene variant and diuretics on the risk of myocardial infarction. *J Hypertens* 2009;27:61-8.
257. Schellens JHM, Grouls R, Guchelaar HJ, Touw DJ, Rongen GA, De Boer A, Van Bortel LM. The dutch vision of clinical pharmacology. *Clin Pharmacol Ther* 2009;85:366-8
258. Van Wieren-de Weier BMA, Maitland-van der Zee AH, De Boer A, Lievers KJA, Kroon AA, De Leeuw PW, Schiffers P, Jansen RGJH, Psaty BM, Bozkurt O, Van Duijn CM, Stricker BHC, Klungel OH. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. *Pharm World Sci* 2009;31:158-64
259. Bozkurt O, De Boer A, Grobbee DE, De Leeuw PW, Kroon AA, Schiffers P, Klungel OH. Variation in renin-angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. *Am J Hypertens* 2009;22:545-51
260. Klungel OH, De Boer A. Visie op statines blijft. Wel nadere studie nodig rol statines bij diabetes *Pharm Weekbl* 2009;december:16-20
261. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, Janssen RG, Psaty BM, van Duijn CM, Stricker BH, Klungel OH. Reasons for non-response in observational pharmacogenetic research. *Pharmacoepidemiol Drug Saf*. 2009;18:665-71.
262. Kars M, Souverein PC, Herings RM, Romijn JA, Vandenbroucke JP, de Boer A, Dekkers OM. Estimated age- and sex-specific incidence and prevalence of dopamine agonist treated hyperprolactinemia. *J Clin Endocrinol Metab*. 2009;94:2729-34
263. Bozkurt O, De Boer A, Grobbee DE, Kroon AA, Schiffers P, De Leeuw P, Klungel OH. Renin-angiotensin system polymorphism and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes. *J Renin Angiotensin Aldosterone Syst* 2009;10:101-8.
264. Pouwels S, Lalmohamed A, Leufkens HGM, de Boer A, Cooper C, van Staa T, de Vries F. Risk of hip/femur fracture after stroke. A population-based case-control study. *Stroke* 2009;40:3281-5
265. Van Schie RMF, Jorgensen AJ, De Boer A, Maitland-van der Zee AH, and for the EU-PACT study group. Systematic review of pharmacogenetic warfarin dosing. *J Gen Intern Med* 2009;24:1171
266. Peters BJM, Klungel OH, De Boer A, Maitland-van der Zee AH. Genetic determinants of response to statins. *Expert Rev Cardiovasc Ther* 2009;7:977-83
267. Van Schie RMF, Kamali F, Daly AK, Vangelis GM, De boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becker E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, Maitland-van der Zee AH. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. *Pharmacogenomics* 2009;10:1287-95
268. van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Belitser S, Kroon AA, de Leeuw PW, Schiffers P, Janssen RG, van Duijn CM, Stricker BH, Klungel OH. Determinants of DNA yield and purity collected with buccal cell samples. *Eur J Epidemiol* 2009;24:677-82

269. Peters BJM, Klungel OH, Visseren FL, De Boer A, Maitland-van der Zee AH. Pharmacogenomic insights into treatment and management of statin-induced myopathy. *Genome Medicine* 2009;1:120.1-120.4
270. Schalekamp T, De Boer A. Pharmacogenetics of oral anticoagulant therapy. *Curr Pharm Des.* 2010;16:187-203.
271. Harmsze A, Van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH. Besides CYP2C19\*2, the variant allele CYP2C9\*3 is associated with higher om-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. *Pharmacogenet Genomics* 2010;20:18-25.
272. Pouwels S, Lalmohamed A, Leufkens HGM, de Boer A, Cooper C, van Staa T, de Vries F. Response to letter by Tsuda. *Stroke* 2010;41:e60
273. Dekkers OM, Romijn JA, De Boer A, Vandenbroucke JP. The risk of breast cancer is not evidently increased in women with hyperprolactinemia. *Pituitary* 2010;13:195-8.
274. Taverne K, De Groot M, De Boer A, Klungel OH. Genetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugs. *Expert Opin. Drug Metab. Toxicol.* 2010;6:439-60.
275. Peters BJM, Rodin AS, De Boer A, Maitland-van der Zee AH. Methodological and statistical issues in pharmacogenomics. *Journal of Pharmacy and pharmacology* 2010;62:161-6
276. Pouwels S, Lalmohamed A, Van Staa T, Cooper C, Souverein PC, Leufkens HGM, Rejnmark JL, de Boer A, Vestergaard P, de Vries F. Use of organic nitrates and the risk of hip fracture: a population-based case-control study. *J Clin Endocrinol Metab* 2010;95:1924-31
277. Harmsze A, Van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. *Thromb Haemost* 2010;103:920-5
278. Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, De Boer A, Maitland-van der Zee AH. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. *Pharmacogenomics* 2010;11:989-1002.
279. Wangge G, Klungel OH, Roes KC, de Boer A, Hoes AW, Knol MJ. Interpretation and inference in noninferiority randomized controlled trials in drug research. *Clin Pharmacol Ther.* 2010;88:420-3
280. Verhoef TI, Schalekamp T, Redekop WK, De Boer A, Maitland-van der Zee A.H. Clinical and economic consequences of pharmacogenetic-guided dosing. *Expert Rev Pharmacoeconomics Outcomes Res* 2010;10:375-8
281. Peters BJ, Rodin AS, Klungel OH, van Duijn CM, Stricker BH, van't Slot R, de Boer A, Maitland-van der Zee AH. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. *Pharmacogenomics.* 2010;11:1065-76.
282. Harmsze AM, Deneer VH, Maitland-van der Zee AH, de Boer A, Klungel OH. Genetic variations affect drug safety and efficacy. *Ned Tijdschr Geneesk.* 2010;154:A1503
283. Harmsze AM, van Werkum JW, Ten Berg JM, Zwart B, Bouman HJ, Breet NJ, van 't Hof AW, Ruven HJ, Hackeng CM, Klungel OH, de Boer A, Deneer VH. CYP2C19\*2 and CYP2C9\*3 alleles are associated with stent thrombosis: a case-control study. *Eur Heart J.* 2010;31:3046-53.
284. Peters BJM, Rodin AS, Klungel OH, Stricker BH, de Boer A, Maitland-van der Zee AH. Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. *Pharmacogenet Genomics.* 2010;210:766-74
285. Wangge G, Klungel OH, Roes KC, de Boer A, Hoes AW, Knol MJ. Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. *PLoS One.* 2010 Oct 27;5(10):e13550.
286. Mattila TK, De Boer A. Influence of Intensive Versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Patients. *Drugs.* 2010;70:2229-45
287. Eussen SRBM, Van der Elst ME, Klungel OH, Rompelberg CJM, Garssen J, Oosterveld MH, De Boer A, De Gier JJ, Bouvy ML. A pharmaceutical care program to improve adherence to statin therapy: a randomized trial. *Ann Pharmacother* 2010;44:1905-13

288. Egberts ACG, De Boer A. Gescheiden farmaceutische budgetten: dansen op ijsschotsen. *Ned Tijdschr Geneesk* 2010;154:2376-8
289. Mattila TK, Stoyanova V, Elferink A, Gispens-de Wied C, De Boer A, Wohlfarth T. Insomnia medication: do publications reflect the complete picture of efficacy and safety? *Eur Neuropsychopharmacol* 2011;21:500-7
290. Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG, De Boer A, Van Staa T, De Vries F. Use of proton pump inhibitors and risk of hip/femur fracture: a population based case-control study. *Osteoporos Int* 2011;22:903-10
291. De Peuter OR, Souverein PC, Klungel OH, Buller HR, De Boer A, Kamphuisen PW. Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failure. *Eur J Heart Fail.* 2011;13:220-6
292. Harmsze AM, Van Werkum JW, Moral F, Ten Berg JM, Hackeng CM, Klungel OH, De Boer A, Deneer VH. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. *Platelets* 2011;22:98-102
293. Maitland-van der Zee AH, van Wieren-de Wijer DB, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, Janssen RG, Psaty BM, van Duijn CM, Stricker BH, Klungel OH. Genetic variation in the renin-angiotensin system, use of renin-angiotensin system inhibitors and the risk of myocardial infarction. *J Renin Angiotensin Aldosterone Syst.* 2011;12:208-214
294. De Peuter OR, Lip GYH, Souverein PC, Klungel OH, De Boer A, Buller HR, Kamphuisen PW. Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study. *Eur J Heart Fail.* 2011;13:489-95
295. Lanktree MB, Guo Y, Murtaza M, Glessner JT, Bailey SD, Onland-Moret NC, Lettre G, Ongen H, Rajagopalan R, Johnson T, Shen H, Nelson CP, Klopp N, Baumert J, Padmanabhan S, Pankratz N, Pankow JS, Shah S, Taylor K, Barnard J, Peters BJ, Maloney C, Lobbmeyer MT, Stanton A, Zafarmand MH, Romaine SP, Mehta A, van Iperen EP, Gong Y, Price TS, Smith EN, Kim CE, Li YR, Asselbergs FW, Atwood LD, Bailey KM, Bhatt D, Bauer F, Behr ER, Bhangale T, Boer JM, Boehm BO, Bradfield JP, Brown M, Braund PS, Burton PR, Carty C, Chandrupatla HR, Chen W, Connell J, Dalgeorgou C, de Boer A, Drenos F, Elbers CC, Fang JC, Fox CS, Frackelton EC, Fuchs B, Furlong CE, Gibson Q, Gieger C, Goel A, Grobbee DE, Hastie C, Howard PJ, Huang GH, Johnson WC, Li Q, Kleber ME, Klein BE, Klein R, Kooperberg C, Ky B, Lacroix A, Lanken P, Lathrop M, Li M, Marshall V, Melander O, Mentch FD, Meyer N, Monda KL, Montpetit A, Murugesan G, Nakayama K, Nondahl D, Onipinla A, Rafelt S, Newhouse SJ, Otieno FG, Patel SR, Putt ME, Rodriguez S, Safa RN, Sawyer DB, Schreiner PJ, Simpson C, Sivapalaratnam S, Srinivasan SR, Suver C, Swergold G, Sweitzer NK, Thomas KA, Thorand B, Timpson NJ, Tischfield S, Tobin M, Tomaszewski M, Verschuren WM, Wallace C, Winkelmann B, Zhang H, Zheng D, Zhang L, Zmuda JM, Clarke R, Balmforth AJ, Danesh J, Day IN, Schork NJ, de Bakker PI, Delle C, Duggan D, Hingorani AD, Hirschhorn JN, Hofker MH, Humphries SE, Kivimaki M, Lawlor DA, Kottke-Marchant K, Mega JL, Mitchell BD, Morrow DA, Palmen J, Redline S, Shields DC, Shuldiner AR, Sleiman PM, Smith GD, Farrall M, Jamshidi Y, Christiani DC, Casas JP, Hall AS, Doevendans PA, D Christie J, Berenson GS, Murray SS, Illig T, Dorn GW 2nd, Cappola TP, Boerwinkle E, Sever P, Rader DJ, Reilly MP, Caulfield M, Talmud PJ, Topol E, Engert JC, Wang K, Dominiczak A, Hamsten A, Curtis SP, Silverstein RL, Lange LA, Sabatine MS, Trip M, Saleheen D, Peden JF, Cruickshanks KJ, Marz W, O'Connell JR, Klungel OH, Wijmenga C, Maitland-van der Zee AH, Schadt EE, Johnson JA, Jarvik GP, Papanicolaou GJ; Hugh Watkins on behalf of PROCARDIS, Grant SF, Munroe PB, North KE, Samani NJ, Koenig W, Gaunt TR, Anand SS, van der Schouw YT; Meena Kumari on behalf of the Whitehall II Study the WHII 50K Group, Soranzo N, Fitzgerald GA, Reiner A, Hegele RA, Hakonarson H, Keating BJ. Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. *Am J Hum Genet.* 2011;88:6-18
296. Peters BJ, Harmsze AM, Ten Berg JM, Maitland-van der Zee AH, Tjoeng MM, de Boer A, Deneer VH. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel. *Pharmacogenomics.* 2011;12:141-4
297. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, Engert JC, Clarke R, Davey-Smith G, Nordestgaard BG, Saleheen D, Samani NJ, Sandhu M, Anand S, Pepys MB, Smeeth L, Whittaker J, Casas JP, Thompson SG, Hingorani AD, Danesh J. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. *BMJ.* 2011 Feb 15;342:d548. doi: 10.1136/bmj.d548.
298. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen JM, van Schaik RHN, Schalekamp T, Touw DJ, van der Weide J,



- Wilffert B, Deneer VHM, Guchelaar HJ. Pharmacogenetics: From Bench to Byte - An Update of Guidelines. *Clin Pharmacol Ther* 2011;89:662-73
299. Biere-Rafi S, Di Nisio M, Gerdes V, Porreca E, Souverein PC, de Boer A, Buller H, Kamphuisen PW. Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism. *Pharmacoepidemiol Drug Saf* 2011;20:635-42
300. Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH, Cats A. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. *Clin Cancer Res* 2011;17:3455-68
301. Van Schie RMF, Wessels JAM, Le Cessie S, De Boer A, Schalekamp S, Van der Meer FJM, Verhoef TI, Van Meegen E, Rosendaal FR, Maitland-van der Zee AH for the EUPACT Study Group. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. *Eur Heart J*;2011: 32:1909-1917
302. Eussen SRBM, Bouvy ML, Rempelberg CJM, Van der Elst ME, Garssen J, Oosterveld MH, De Boer A, De Gier JJ, Van Kranen HJ, Klungel OH. Influence of the use of functional foods enriched with phytosterols/-stanols on adherence to statin therapy. *Pharmacoepidemiol Drug Saf* 2011;20:830-7
303. Harmsze AM, van Werkum JW, ten Berg JM, Ruven HJT, Hackeng CM, Tjoeng MM, Klungel OH, De Boer A, Deneer V. Effect van genetische variaties op de effectiviteit van Clopidogrel. *PW Scientific edition* 2011;5:a1111.
304. Peters BJ, Pett H, Klungel OH, Stricker BH, Psaty BM, Glazer NL, Wiggins KL, Bis JC, de Boer A, Maitland-van der Zee AH. Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. *Atherosclerosis*. 2011; 217:458-464.
305. Harmsze AM, De Boer A, Boot H, Deneer VHM, Heringa M, De Mol PGM, Schalekamp T, Verduijn MM, Verheugt FWA, le Comte M. Interactie tussen clopidogrel en protonpompremmers. *Ned Tijdschr Geneesk* 2011;155:A2442
306. Belitser SV, Martens EP, Pestman WR, Groenwold RHH, de Boer A, Klungel OH. Measuring balance and model selection in propensity score methods. *Pharmacoepidemiol Drug Saf* 2011;20:1115-29
307. Bazelier M, de Boer A, de Vries F. Acid suppressants and hip fracture: Duplicate publication bias? *Bone* 2011; 49:920
308. De Boer A. When to publish measures of disproportionality derived from spontaneous reporting databases? *Br J Clin Pharmacol* 2011;72:909-11
309. Harmsze AM, van Werkum JW, Souverein PC, Breet NJ, Bouman HJ, Hackeng CM, Ruven HJ, Ten Berg JM, Klungel OH, de Boer A, Deneer VH. Combined influence of proton-pump-inhibitors, calcium-channel-blockers and CYP2C9\*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. *J Thromb Haemost*. 2011;9:1892-901
310. Van Schie RM, de Boer A, Maitland-van der Zee AH. Implementation of pharmacogenetics in clinical practice is challenging. *Pharmacogenomics*. 2011;12:1231-3
311. Blom MT, Bardai A, van Munster BC, Nieuwland MI, de Jong H, van Hoeijen DA, Spanjaart A, de Boer A, de Rooij SE, Tan HL. Differential Changes in QTc Duration during In-hospital Haloperidol Use. *PLoS ONE* 2011;6(9): e23728. Correction: Differential Changes in QTc Duration during In-Hospital Haloperidol Use. *PLoS One*. 2012;7(7). doi: 10.1371/annotation/92655d2b-fac1-4641-970c-a8e4fb5739fc.
312. Groenwold RHH, de Vries F, de Boer A, Pestman WR, Rutten FH, Hoes AW, Klungel OH. Balance measures for propensity score methods: a clinical example on beta-agonist use and the risk of myocardial infarction *Pharmacoepidemiol Drug Saf* 2011;20:1130-7
- 313 The ICB 50K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. *Plos Genetics* 2011;7(9):e1002260. doi:10.371/journal.pgen.1002260.
- 314 Van den Hoek H, Bos WJW, De Boer A, Van de Garde EW. Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials. *BMJ* 2011;343:d7281 doi: 10.1136/bmj.d7281
315. Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F, EU-PACT Study Group. Collaborators: de Boer A, Daly AK, Haschke-Becher E, Kamali F, Maitland-van der Zee AH, Manolopoulos VG, Pirmohamed M, Redekop WK, Rosendaal FR, Stingl J, Wadelius M. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. *Clin Pharmacol Ther*. 2011;90:701-6.

316. Lalmohamed A, Welsing PM, Lems WF, Jacobs JW, Kanis JA, Johansson H, De Boer A, De Vries F. Calibration of FRAX (R) 3.1 to the Dutch population with data on the epidemiology of hip fractures. *Osteoporos Int* 2012;23:861-9
317. Harmsze AM, van Werkum JW, Hackeng CM, Ruven HJ, Kelder JC, Bouman HJ, Breet NJ, Ten Berg JM, Klungel OH, de Boer A, Deneer VH. The influence of CYP2C19\*2 and \*17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. *Pharmacogenet Genomics*. 2012;22:169-75
318. Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, Lanktree MB, Tare A, Castillo BA, Li YR, Johnson T, Bruinenberg M, Gilbert-Diamond D, Rajagopalan R, Voight BF, Balasubramanyam A, Barnard J, Bauer F, Baumert J, Bhangale T, Bohm BO, Braund PS, Burton PR, Chandrupatla HR, Clarke R, Cooper-Dehoff RM, Crook ED, Davey-Smith G, Day IN, de Boer A, de Groot MC, Drenos F, Ferguson J, Fox CS, Furlong CE, Gibson Q, Gieger C, Gilhuijs-Pederson LA, Glessner JT, Goel A, Gong Y, Grant SF, Grobbee DE, Hastie C, Humphries SE, Kim CE, Kivimaki M, Kleber M, Meisinger C, Kumari M, Langae TY, Lawlor DA, Li M, Lobbmeyer MT, Maitland-van der Zee AH, Meijis MF, Molony CM, Morrow DA, Murugesan G, Musani SK, Nelson CP, Newhouse SJ, O'Connell JR, Padmanabhan S, Palmen J, Patel SR, Pepine CJ, Pettinger M, Price TS, Rafelt S, Ranchalis J, Rasheed A, Rosenthal E, Ruczinski I, Shah S, Shen H, Silbernagel G, Smith EN, Spijkerman AW, Stanton A, Steffes MW, Thorand B, Trip M, van der Harst P, van der A DL, van Iperen EP, van Setten J, van Vliet-Ostapchouk JV, Verweij N, Woffenbuttel BH, Young T, Zafarmand MH, Zmuda JM; the Look AHEAD Research Group; DIAGRAM consortium, Boehnke M, Altshuler D, McCarthy M, Kao WH, Pankow JS, Cappola TP, Caulfield M, Dominiczak A, Shields DC, Bhatt D, Zhang L, Curtis SP, Danesh J, Casas JP, van der Schouw YT, Onland-Moret NC, Doevendans PA, Dorn GW 2nd, Farrall M, Fitzgerald GA, Hamsten A, Hegele R, Hingorani AD, Hofker MH, Huggins GS, Illig T, Jarvik GP, Johnson JA, Klungel OH, Knowler WC, Koenig W, Marz W, Meigs JB, Melander O, Munroe PB, Mitchell BD, Bielinski SJ, Rader DJ, Reilly MP, Rich SS, Rotter JI, Saleheen D, Samani NJ, Schadt EE, Shuldiner AR, Silverstein R, Kottke-Marchant K, Talmud PJ, Watkins H, Asselbergs F, de Bakker PI, McCaffery J, Wijmenga C, Sabatine MS, Wilson JG, Reiner A, Bowden DW, Hakonarson H, Siscovick DS, Keating BJ. Large-Scale Gene-Centric Meta-Analysis across 39 studies Identifies Type 2 Diabetes Loci. *Am J Hum Genet*. 2012;90:410-25
319. Clarke R, Bennett DA, Parish S, Verhoef P, Doi Tsch-Klerk M, Lathrop M, Xu P, Nordestgaard BG, Holm H, Hopewell JC, Saleheen D, Tanaka T, Anand SS, Chambers JC, Kleber ME, Ouwehand WH, Yamada Y, Elbers C, Peters BJ, Stewart AFR, Reilly MM, Thorand B, Yusuf S, Engert JC, Assimes TL, Kooner J, Danesh J, Watkins H, Samani NJ, Collins R, Peto R, for the MTHFR Studies Collaborative Group. Homocysteine and Coronary Heart Disease: Meta-analysis of MTHFR Case-Control Studies, Avoiding Publication Bias. *PLoS Med* 2012;9(2): e1001177. doi:10.1371/journal.pmed.1001177
320. Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, van der Meer FJ, le Cessie S, Wessels JA, van Schie RM, de Boer A, Teichert M, Visser LE, Maitland-van der Zee AH; on behalf of the EU-PACT group. Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in acenocoumarol users. *J Thromb Haemost*. 2012;10:606-14
321. van Vliet-Ostapchouk JV, van Haeften TW, Landman GWD, Reiling E, Kleefstra N, Bilo HJG, Klungel OH, de Boer A, van Diemen CC, Wijmenga C, Boezen HM, Dekker JM, van 't Riet E, Nijpels G, Welschen LMC, Zavrelava H, Bruin EJ, Elbers CC, Bauer F, Onland-Moret NC, van der Schouw YT, Grobbee DE, Spijkerman AMW, van der A DL, Simonis-Bik AM, Eekhoff EM, Diamant M, Kramer MHH, Boomsma DI, de Geus EJ, Willemsen G, Slagboom PE, Hofker MH, 't Hart LM. Common variants in the type 2 diabetes KCNQ1 gene are associated with impairments in insulin secretion during hyperglycaemic glucose clamp. *PLoS ONE* 2012;7(3):e32148. *PLoS One*. 2012;7(6). doi: 10.1371/annotation/d44162c6-c882-4f98-b355-4feedd1a8f46. Epub 2012 Jun 13
322. Lalmohamed A, Bazelier MT, Van Staa TP, Uitdehaag BMJ, Leufken HGM, De Boer A, De Vries F. Causes of Death in Patients with Multiple Sclerosis and Matched Referent Subjects: a Population-based Cohort Study. *Eur J Neurol* 2012;19:1007-14.
323. van Schie RM, Babajeff AM, Schalekamp T, Wessels JA, le Cessie S, de Boer A, van der Meer FJ, van Meegen E, Verhoef TI, Rosendaal FR, Maitland-van der Zee AH; for the EU-PACT study group. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. *J Thromb Haemost*. 2012;10:767-72
324. IL6R MR Consortium. The interleukin-6 receptor as a target for coronary heart disease: a Mendelian randomization analysis. *Lancet* 2012;379:1214-24
325. Verhoef TI, Zuurhout MJ, van Schie RM, Redekop WK, van der Meer FJ, le Cessie S, Schalekamp T, de Boer A, Maitland-van der Zee AH. The effect of omeprazole and esomeprazole

on the maintenance dose of phenprocoumon. *Br J Clin Pharmacol.* 2012;74:1068-9

326. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Holm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PIW, Klungel OH, Maitland-van der Zee AH, Peters BJM, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VHM, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie P, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Linsel-Nitschke P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buyschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeier J, Schreiber S, Schafer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet* 2012;380:572-80. Erratum in: *Lancet.* 2012;380:564.
327. De Boer A, Maitland-van der Zee AH. Implementatie van farmacogenetica in de klinische praktijk: dermatologisch perspectief. *Nederlands Tijdschrift voor Dermatologie & Venereologie.* 2012;22:171-3
328. Van Schie RMF, Verhoef TI, Maitland-Van Der Zee AH, de Boer A, Schalekamp T, Van Der Meer FJM, Redekop WK, Thariani R. "Future of Pharmacogenetics in Cardiovascular Diseases" in *Pharmacology 2012*, ISBN: 978-953-51-0222-9 pp 207-222
329. Lalmohamed A, Vestergaard P, Klop C, Grove EL, de Boer A, Leufkens HG, van Staa TP, de Vries F. Timing of Acute Myocardial Infarction in Patients Undergoing Total Hip or Knee Replacement: A Nationwide Cohort Study. *Arch Intern Med.* 2012;172:1229-35
330. Kleijnen S, George E, Goulden S, d'Andon A, Vitre P, Osinska B, Rdzany R, Thirstrup S, Corbacho B, Nagy BZ, Leufkens HG, de Boer A, Goettsch WG. Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions. *Value Health.* 2012;15:954-60.
331. van Schie RM, El Khedr N, Verhoef TI, Teichert M, Stricker BH, Hofman A, Buhre PN, Wessels JA, Schalekamp T, le Cessie S, van der Meer FJ, Rosendaal FR, de Boer A, Maitland-van der Zee AH, Visser LE. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. *Pharmacogenomics.* 2012;13:1239-45.
332. Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin LA, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH; The EU-PACT group. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. *Pharmacogenomics* 2012;13:1405-17
333. Warnier MJ, Rutten FH, Kors JA, Lammers JW, de Boer A, Hoes AW, de Bruin ML. Cardiac Arrhythmias in Adult Patients with Asthma. *J Asthma* 2012;49:942-6
334. Verhoef TI, Redekop WK, Hegazy H, de Boer A, Maitland-van der Zee AH; The EU-PACT group. Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. *J Thromb Haemost.* 2012;10:2610-12
335. van Schie RM, Verhoef TI, Boejharat SB, Schalekamp T, Wessels JA, le Cessie S, Rosendaal FR, van der Meer FJ, de Boer A, Maitland-van der Zee AH. Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose. *Drug Metabol Drug Interact.* 2012;27:229-34
336. Lalmohamed A, Vestergaard P, Cooper C, de Boer A, Leufkens HG, van Staa TP, de Vries F. Timing of Stroke in Patients Undergoing Total Hip Replacement and Matched Controls: A Nationwide Cohort Study. *Stroke* 2012;43:3225-9
337. van Schie RMF, Wessels JAM, Verhoef TI, Schalekamp T, le Cessie S, van der Meer FJM, Rosendaal FR, Visser LE, Teichert M, Hofman A, Buhre PNM, de Boer A, Maitland-van der Zee AH. Evaluation of the effect of genetic variations in GATA 4 on the phenprocoumon and acenocoumarol maintenance dose. *Pharmacogenomics* 2012;13:1917-23
338. Pouwels S, de Boer A, Javaid MK, Hilton-Jones D, Verschuuren J, Cooper C, Leufkens HG, de Vries F. Fracture rate in patients with myasthenia gravis: the general practice research database. *Osteoporos Int.* 2013;24:467-76

339. Wangge G, Roes KC, de Boer A, Hoes AW, Knol MJ. The challenges of determining non-inferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants. *CMAJ* 2013;185:222-7
340. Blom MT, Warnier MJ, Bardai A, Berdowski J, Koster RW, Souverein PC, Hoes AW, Rutten FH, de Boer A, de Bruin ML, Tan HL. Reduced in-hospital survival rates of out-of-hospital cardiac arrest victims with obstructive pulmonary disease. *Resuscitation* 2013;84:569-74
341. Stuijver DJ, Majoor CJ, van Zaane B, Souverein PC, de Boer A, Dekkers OM, Buller HR, Gerdes VE. Use of oral Glucocorticoids and the Risk of Pulmonary Embolism: A Population-Based Case-Control Study. *Chest* 2013;143:1337-42
342. Wangge G, Klungel OH, Roes KC, de Boer A, Hoes AW, Knol MJ. Should non-inferiority drug trials be banned altogether? *Drug Discov Today*. 2013;18:601-4
343. Ali MS, Groenwold RH, Pestman WR, Belitser SV, Hoes AW, de Boer A, Klungel OH. Time-dependent propensity score and collider-stratification bias: an example of beta(2)-agonist use and the risk of coronary heart disease. *Eur J Epidemiol*. 2013;28:291-9
344. Lalmohamed A, Vestergaard P, Jansen PAF, Grove EL, de Boer A, Leufkens HGM, van Staa TP, de Vries F. Prolonged outpatient vitamin K antagonist use and risk of venous thromboembolism in patients undergoing total hip or knee replacement. *J Thromb Haemost*. 2013;11:642-50
345. Biere-Rafi S, Hutten BA, Squizzato A, Ageno W, Souverein PC, de Boer A, Gerdes VEA, Buller HR, Kamphuisen PW. Statin treatment and the risk of recurrent pulmonary embolism. *Eur Heart J*. 2013;34:1800-6
346. Mahmoudpour SH, Leusink M, Putten Lv, Terreehorst I, Asselbergs FW, de Boer A, Maitland-van der Zee AH. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. *Pharmacogenomics*. 2013;14:249-60
347. Warnier MJ, Rutten FH, Numans ME, Kors JA, Tan HL, de Boer A, Hoes AW, De Bruin ML. Electrocardiographic characteristics of patients with chronic obstructive pulmonary disease. *COPD* 2013;10:62-71
348. Bardai A, Amin AS, Blom MT, Bezzina CR, Berdowski J, Langendijk PN, Beekman L, Klemens CA, Souverein PC, Koster RW, de Boer A, Tan HL. Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. *Eur Heart J*. 2013;34:1506-16
349. Pouwels S, Bazelier MT, de Boer A, Weber WE, Neef C, Cooper C, de Vries F. Risk of fracture in patients with Parkinson's disease. *Osteoporos Int*. 2013;24:2283-90
350. Wangge G, de Boer A, Klungel OH, Hoes AW, Knol MJ. Expert-opinion on non-inferiority margin: A case study of oral anti-coagulant agents for prophylaxis of venous thromboembolic events after orthopedic surgery. *Thromb Res*. 2013;131:368-71
351. Duijnhoven RG, Straus SMJM, Raine JM, de Boer A, Hoes AW, de Bruijn ML. Number of patients studied prior to approval of new medicines: a database analysis. *PLoS Med* 2013;10(3): e1001407. doi:10.1371/journal.pmed.1001407
352. van Schie RM, Aoussar A, van der Meer FJ, de Boer A, Maitland-van der Zee AH. Evaluation of the effect of SNPs in CYP3A4 and CYP4F2 on the stable phenprocoumon and acenocoumarol maintenance dose. *J Thromb Haemost*. 2013;11:1200-3
353. Groenwold RH, Klungel OH, Altman DG, van der Graaf Y, Hoes AW, Moons KG; PROTECT WP2 (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium, Work Programme 2 [Framework for pharmacoepidemiology studies]. Adjustment for continuous confounders: an example of how to prevent residual confounding. *CMAJ*. 2013;185:401-6
354. Schmidt AF, Rovers MM, Klungel OH, Hoes AW, Knol MJ, Nielsen M, de Boer A, Groenwold RH. Differences in interaction and subgroup-specific effects were observed between randomized and nonrandomized studies in three empirical examples. *J Clin Epidemiol*. 2013;66:599-607
355. Sontoredjo TA, de Boer A, Maitland-van der Zee AH. Etnische farmacogenetica. *Ned Tijdschr Geneeskd*. 2013;157:A6118.
356. van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, Verhoef TI, van Meegen E, Rosendaal FR, Maitland-van der Zee AH; EU-PACT Study Group. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. *Eur Heart J*. 2011 Aug;32(15):1909-17. doi: 10.1093/eurheartj/ehr116. Epub 2011 Jun 2. Erratum in: *Eur Heart J*. 2013 Jun;34(24):1854.

357. Lalmohamed A, Vestergaard P, Javaid MK, de Boer A, Leufkens HG, van Staa TP, de Vries F. Risk of gastrointestinal bleeding in patients undergoing total hip or knee replacement compared with matched controls: a nationwide cohort study. *Am J Gastroenterol.* 2013;108:1277-85
358. Fazeli Farsani S, van der Aa MP, van der Vorst MM, Knibbe CA, de Boer A. Global trends in the incidence and prevalence of type 2 diabetes in children and adolescents: a systematic review and evaluation of methodological approaches. *Diabetologia* 2013;56:1471-88
359. Bernabe RD, Wangge G, Knol MJ, Klungel OH, van Delden JJ, de Boer A, Hoes AW, Raaijmakers JA, van Thiel GJ. Phase IV non-inferiority trials and additional claims of benefit. *BMC Med Res Methodol.* 2013;13:70.
360. Verhoef TI, Redekop WK, Veenstra DL, Thariani R, Beltman PA, van Schie RM, de Boer A, Maitland-van der Zee AH; Members of the EU-PACT group. Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. *Pharmacogenomics.* 2013;14:869-83
361. Kooy MJ, van Wijk BL, Heerdink ER, de Boer A, Bouvy ML. Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. *Front Pharmacol.* 2013 May 29;4:69. doi: 10.3389/fphar.2013.00069. Print 2013.
362. Warnier MJ, Blom MT, Bardai A, Berdowski J, Souverein PC, Hoes AW, Rutten FH, de Boer A, Koster RW, De Bruin ML, Tan HL. Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study. *PLoS One.* 2013 Jun 6;8(6):e65638. doi: 10.1371/journal.pone.0065638. Print 2013.
363. Pouwels S, Bazelier MT, de Boer A, Weber WE, Neef CK, Cooper C, de Vries F. Five-year fracture risk estimation in patients with Parkinson's disease. *Bone.* 2013;56:266-70
364. Franken M, Nilsson F, Sandmann F, de Boer A, Koopmanschap M. Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. *Pharmacoeconomics* 2013;31:781-97
365. Donnelly LA, van Zuydam NR, Zhou K, Tavendale R, Carr F, Maitland-van der Zee AH, Leusink M, de Boer A, Doevendans PA, Asselbergs FW, Morris AD, Pearson ER, Klungel OH, Doney AS, Palmer CN. Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. *Pharmacogenet Genomics.* 2013;23:518-25
366. Schmidt AF, Nielen M, Klungel OH, Hoes AW, de Boer A, Groenwold RHH, Investigators VSSO, Kirpensteijn J. Prognostic Factors of Early Metastasis and Mortality in Dogs with Appendicular Osteosarcoma after Receiving Surgery: An Individual Patient Data Meta-Analysis. *Prev Vet Med.* 2013;112:414-22
367. Wangge G, Putzeist M, Knol MJ, Klungel OH, Gispens-De Wied CC, de Boer A, Hoes AW, Leufkens HG, Mantel-Teeuwisse AK. Regulatory scientific advice on non-inferiority drug trials. *PLoS One.* 2013 Sep 5;8(9):e74818. doi: 10.1371/journal.pone.0074818.
368. Van Schie RMF, de Boer A, van der Meer FJM, Maitland-van der Zee AH. Op weg naar een optimale dosering van cumarinederivaten. *Pharmaceutisch Weekblad* 2013;37:24-7
369. Starup-Linde J, Karlstad O, Eriksen SA, Vestergaard P, Bronsveld HK, Vries FD, Andersen M, Auvinen A, Haukka J, Hjellvik V, Bazelier M, de Boer A, Furu K, De Bruin M. CARING (CAncer Risk and INsulin analogues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants- a Systematic Review and a Meta-Analysis. *Curr Drug Saf.* 2013;8:296-332
370. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJM, Redekop WK, Remkes M, Rosendaal FR, van Schie RMF, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH for the EU-PACT Group. A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon. *N Engl J Med.* 2013;369:2304-12
371. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. *N Engl J Med.* 2013;369:2294-303
372. Verhoef TI, Redekop WK, Daly AK, van Schie RM, de Boer A, Maitland-van der Zee AH. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol

- and phenprocoumon. *Br J Clin Pharmacol.* 2014;77:626-41.
373. Pouwels S, de Boer A, Leufkens HGM, Weber WEJ, Cooper C, van Onzenoort HAW, de Vries F. Risk of fracture in patients with muscular dystrophies. *Osteoporos Int* 2014;25:509-18.
374. Leusink M, Onland-Moret NC, Asselbergs FW, Ding B, Kotti S, van Zuydam NR, Papp AC, Danchin N, Donnelly L, Morris AD, Chasman DI, Doevendans PA, Klungel OH, Ridker PM, van Gilst WH, Simon T, Nyberg F, Palmer CN, Sadee W, van der Harst P, de Bakker PI, de Boer A, Verstuyft C, Maitland-van der Zee AH. Cholesteryl ester transfer protein (CETP) polymorphisms, statin use, and their impact on cholesterol levels and cardiovascular events. *Clin Pharmacol Ther.* 2014;95:314-20
375. Van der Aa MP, Fazeli Farsani S, Kromwijk LA, de Boer A, Knibbe CA, van der Vorst MM. How to Screen Obese Children at Risk for Type 2 Diabetes Mellitus? *Clin Pediatr (Phila).* 2014;53:337-42
376. Uddin MJ, Groenwold RH, de Boer A, Belitser SV, Roes KC, Hoes AW, Klungel OH. Performance of instrumental variable methods in cohort and nested case-control studies: a simulation study. *Pharmacoepidemiol Drug Saf.* 2014;23:165-77
377. Lalmohamed A, Vestergaard P, de Boer A, Leufkens HG, van Staa TP, de Vries F. Changes in mortality patterns following total hip or knee replacement over the past two decades: A nationwide cohort study. *Arthritis Rheumatol.* 2014;66:311-8
378. Bazargani YT, de Boer A, Schellens JH, Leufkens HG, Mantel-Teeuwisse AK. Selection of oncology medicines in low- and middle-income countries. *Ann Oncol.* 2014;25:270-6
379. Ali MS, Groenwold RH, Pestman WR, Belitser SV, Roes KC, Hoes AW, de Boer A, Klungel OH. Propensity score balance measures in pharmacoepidemiology: a simulation study. *Pharmacoepidemiol Drug Saf.* 2014;23:802-11. doi: 10.1002/pds.3574.
380. Fazeli Farsani S, Souverein PC, van der Vorst MM, Mantel-Teeuwisse AK, Knibbe CA, de Boer A. Disease history and medication use as risk factors for the clinical manifestation of type 1 diabetes in children and young adults: an explorative case control study. *PLoS One.* 2014 Feb 3;9(2):e87408. doi: 10.1371/journal.pone.0087408. eCollection 2014.
381. Verhoef TI, Redekop WK, Bouvy ML, Dorenbos B, Karwar Z, van Schie RM, de Boer A, Maitland-van der Zee AH; EU-PACT group. Beliefs about medicines in Dutch acenocoumarol and phenprocoumon users. *Br J Clin Pharmacol.* 2014;78:422-9.
382. Bazargani YT, Ewen M, de Boer A, Leufkens HG, Mantel-Teeuwisse AK. Essential Medicines Are More Available than Other Medicines around the Globe. *PLoS One.* 2014 Feb 12;9(2):e87576. doi: 10.1371/journal.pone.0087576. eCollection 2014
383. Yasmina A, Deneer VH, van der Zee AH, van Staa TP, de Boer A, Klungel OH. Application of routine electronic health record databases for pharmacogenetic research. *J Intern Med.* 2014;275:590-604
384. Bazargani YT, de Boer A, Leufkens HG, Mantel-Teeuwisse AK. Essential medicines for COPD and asthma in low and middle-income countries. *Thorax.* 2014 Mar 3. doi: 10.1136/thoraxjnl-2014-205249. [Epub ahead of print]
385. Yasmina A, de Boer A, Klungel OH, Deneer VH. Pharmacogenomics of oral antiplatelet drugs. *Pharmacogenomics.* 2014;15:509-28.
386. Pouwels S, de Boer A, Leufkens HG, Weber WE, Cooper C, de Vries F. Risk of fracture in patients with Charcot-Marie-Tooth disease. *Muscle Nerve.* 2014 Mar 14. doi: 10.1002/mus.24240. [Epub ahead of print]
387. Pouwels S, de Boer A, Leufkens HG, Weber WE, Cooper C, van Staa TP, de Vries F. Risk of fracture in patients with Guillain-Barre syndrome. *Osteoporos Int.* 2014;25:1845-51
388. Schmidt AF, Groenwold RH, Knol MJ, Hoes AW, Nielen M, Roes KC, de Boer A, Klungel OH. Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study. *J Clin Epidemiol.* 2014;67:821-9. doi: 10.1016/j.jclinepi.2014.02.008.
389. Sabate M, Pacheco JF, Ballarin E, Ferrer P, Petri H, Hasford J, Schoonen MW, Rottenkolber M, Fortuny J, Laporte JR, Ibanez L1; PROTECT Work Package 2 A compilation of research working groups on drug utilisation across Europe. *BMC Res Notes.* 2014;7:143. doi: 10.1186/1756-0500-7-143.
390. Maitland-van der Zee AH, de Boer A, Manolopoulos VG; EU-PACT Group. Genotype-guided dosing of vitamin K antagonists. *N Engl J Med.* 2014;370:1765-6
391. Pirmohamed M, Wadelius M, Kamali F; EU-PACT Group. Genotype-guided dosing of vitamin K antagonists. *N Engl J Med.* 2014;370:1764-5.
392. Wilffert B, Swen JJ, Mulder H, van Schaik RHN, Nijenhuis M, Grandia L, Maitland-van der Zee AH, Rongen GA, Schalekamp T, van der Weide J, de Boer A, Guchelaar HJ, Touw DJ, Deneer

- VHM. Implementation of Pharmacogenetics in Evidence-based Medicine: Toward Advancing Personalized Medicine (Chapter 22; pp 953-1116). In *Handbook of personalized medicine. Advances in Nanotechnology, Drug Delivery, and Theory*. Edited by Ioannis S. Vizirianakis. Pan Stanford Publishing 2014 ISBN 978-981-4411-19-6
393. van Schie RM, de Boer A, van der Zee AH. Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses: reply. *J Thromb Haemost*. 2014;12:1197-8. doi: 10.1111/jth.12603.
394. Van der Zee PA, de Boer A. Pheochromocytoma: A review on preoperative treatment with phenoxybenzamine or doxazosin. *Neth J Med*. 2014;72:190-201
395. Fazeli Farsani S, Souverein PC, van der Vorst MM, Knibbe CA, de Boer A, Mantel-Teeuwisse AK. Anti-infective medication use before and after the onset of type 1 diabetes in children and adolescents: a population-based cohort study. *Antimicrob Agents Chemother*. 2014;58:4666-74
396. Warnier MJ, Holtkamp FA, Rutten FH, Hoes AW, de Boer A, Mol PG, De Bruin ML. Quality of drug label information on QT interval prolongation. *Int J Risk Saf Med*. 2014;26:89-98. doi: 10.3233/JRS-140612.
397. Zee AH, Daly AK, Kamali F, Manolopoulos VG, Verhoef TI, Wadelius M, de Boer A, Pirmohamed M. Patients benefit from genetics-guided coumarin anticoagulant therapy. *Clin Pharmacol Ther*. 2014;96:15-7. doi: 10.1038/clpt.2014.44.
398. Bergmeijer TO, Janssen PW, Schipper JC, Qaderdan K, Ishak M, Ruitenbeek RS, Asselbergs FW, van 't Hof AW, Dewilde WJ, Spano F, Herrman JP, Kelder JC, Postma MJ, de Boer A, Deneer VH, Ten Berg JM. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. *Am Heart J*. 2014;168:16-22. doi: 10.1016/j.ahj.2014.03.006.
399. Warnier MJ, Holtkamp FA, Rutten FH, Hoes AW, de Boer A, Mol PG, De Bruin ML. Safety information on QT-interval prolongation: comparison of European and American drug labeling. *Drug Discov Today*. 2014;19:1294-7. doi: 10.1016/j.drudis.2014.06.017. Epub 2014 Jun 25
400. Prieto-Alhambra D, Lalmohamed A, Abrahamsen B, Arden NK, de Boer A, Vestergaard P, de Vries F. Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort. *Arthritis Rheumatol*. 2014;66:3233-40. doi: 10.1002/art.38789
401. Ali MS, Uddin MJ, Groenwold RH, Pestman WR, Belitser SV, Hoes AW, de Boer A, Roes KC, Klungel OH. Quantitative falsification of instrumental variables assumption using balance measures. *Epidemiology*. 2014;25:770-2. doi: 10.1097/EDE.0000000000000152.
402. Kreeftmeijer-Vegter A, de Boer A, van der Vlugt-Meijer RH, de Vries PJ. The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children. *Orphanet J Rare Dis*. 2014 Aug 5;9(1):120. doi: 10.1186/s13023-014-0120-x.
403. Baranova EV, de Boer A, Maitland-van der Zee AH. The COAG and EU-PACT Trials: What is the Clinical Benefit of Pharmacogenetic-Guided Coumarin Dosing During Therapy Initiation? *Curr Mol Med*. 2014;14:841-8. Review
404. Duijnhoven RG, Straus SMJM, Souverein PC, de Boer A, Bosch JLHR, Hoes HW, De Bruin ML. Long-term use of 5 $\alpha$ -reductase inhibitors and the risk of male breast cancer. *Cancer Causes Control*. 2014 Nov;25(11):1577-82. doi: 10.1007/s10552-014-0455-6. Epub 2014 Aug 19
405. Warnier MJ, Rutten FH, de Boer A, Hoes AW, De Bruin ML. Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumonia. *PLoS One*. 2014 Aug 26;9(8):e105152. doi: 10.1371/journal.pone.0105152. eCollection 2014.
406. Bazargani YT, de Boer A, Leufkens HG, Mantel-Teeuwisse AK. Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists. *PLoS One*. 2014 Sep 26;9(9):e106072. doi: 10.1371/journal.pone.0106072. eCollection 2014.
407. Leusink M, de Keyser CE, Onland-Moret NC, Hofman A, Visser LE, Stricker BH, de Bakker PI, de Boer A, van Schaik RH, Maitland-van der Zee AH. No association between CYP3A4\*22 and statin effectiveness in reducing the risk for myocardial infarction. *Pharmacogenomics*. 2014;15:1471-7. doi: 10.2217/pgs.14.90.
408. Verhoef TI, Redekop WK, Hasrat F, de Boer A, Maitland-van der Zee AH. Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings. *Am J Cardiovasc Drugs*. 2014;14:451-62. doi: 10.1007/s40256-014-0092-1.
409. Blom MT, van Hoesen DA, Bardai A, Berdowski J, Souverein PC, De Bruin ML, Koster RW, de Boer A, Tan HL. Genetic, clinical and pharmacological determinants of out-of-hospital cardiac arrest: rationale and outline of the AmsteRdam Resuscitation Studies (ARREST) registry. *Open Heart*.

410. Fazeli Farsani S, Souverein PC, van der Vorst MM, Knibbe CA, Herings RM, de Boer A, Mantel-Teeuwisse AK. Increasing trends in the incidence and prevalence rates of type 1 diabetes among children and adolescents in the Netherlands. *Pediatr Diabetes*. 2014 Nov 7. doi: 10.1111/pedi.12232. [Epub ahead of print]

411. Daniel I Swerdlow\*, David Preiss\*, Karoline B Kuchenbaecker, Michael V Holmes, Jorgen E L Engmann, Tina Shah, Reecha Sofat, Stefan Stender, Paul C D Johnson, Robert A Scott, Maarten Leusink, Niek Verweij, Stephen J Sharp, Yiran Guo, Claudia iambartolomei, Christina Chung, Anne Peasey, Antoinette Amuzu, KaWah Li, Jutta Palmen, Philip Howard, Jackie A Cooper, Fotios Drenos, Yun R Li, Gordon Lowe, John Gallacher, Marlene C W Stewart, Ioanna Tzoulaki, Sarah G Buxbaum, Daphne L van der A, Nita G Forouhi, N Charlotte Onland-Moret, Yvonne T van der Schouw, Renate B Schnabel, Jaroslav A Hubacek, Ruzena Kubinova, Migle Baceviciene, Abdonas Tamosiunas, Andrzej Pajak, Roman Topor-Madry, Urszula Stepaniak, Sofi a Malyutina, Damiano Baldassarre, Bengt Sennblad, Elena Tremoli, Ulf de Faire, Fabrizio Veglia, Ian Ford, J Wouter Jukema, Rudi G J Westendorp, Gert Jan de Borst, Pim A de Jong, Ale Algra, Wilko Spiering, Anke H Maitland-van der Zee, Olaf H Klungel, Anthonius de Boer, Pieter A Doevendans, Charles B Eaton, Jennifer G Robinson, David Duggan, DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium, John Kjekshus, John R Downs, Antonio M Gotto, Anthony C Keech, Roberto Marchioli, Gianni Tognoni, Peter S Sever, Neil R Poulter, David D Waters, Terje R Pedersen, Pierre Amarenco, Haruo Nakamura, John J V McMurray, James D Lewsey, Daniel I Chasman, Paul M Ridker, Aldo P Maggioni, Luigi Tavazzi, Kausik K Ray, Sreenivasa Rao Kondapally Seshasai, JoAnn E Manson, Jackie F Price, Peter H Whincup, Richard W Morris, Debbie A Lawlor, George Davey Smith, Yoav Ben-Shlomo, Pamela J Schreiner, Myriam Fornage, David S Siscovick, Mary Cushman, Meena Kumari,

Nick J Wareham, W M Monique Verschuren, Susan Redline, Sanjay R Patel, John C Whittaker, Anders Hamsten, Joseph A Delaney, Caroline Dale, Tom R Gaunt, Andrew Wong, Diana Kuh, Rebecca Hardy, Sekar Kathiresan, Berta A Castillo, Pim van der Harst, Eric J Brunner, Anne Tybjaerg-Hansen, Michael G Marmot, Ronald M Krauss, Michael Tsai, Josef Coresh, Ronald C Hoogeveen, Bruce M Psaty, Leslie A Lange, Hakon Hakonarson, Frank Dudbridge, Steve E Humphries, Philippa J Talmud, Mika Kivimaki, Nicholas J Simpson, Claudia Langenberg, Folkert W Asselbergs, Mikhail Voevoda, Martin Bobak, Hynek Pikhart, James G Wilson, Alex P Reiner, Brendan J Keating, Aroon D Hingorani,

Naveed Sattar. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet*. 2015 Jan 24;385(9965):351-61. doi: 10.1016/S0140-6736(14)61183-1. Epub 2014 Sep 24.

412. Uddin MJ, Groenwold RH, van Staa TP, de Boer A, Belitser SV, Hoes AW, Roes KC, Klungel OH. Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study. *Pharmacoepidemiol Drug Saf*. 2015;24:468-77. doi: 10.1002/pds.3724. Epub 2014 Nov 20

413. Ali MS, Groenwold RH, Belitser SV, Pestman WR, Hoes AW, Roes KC, Boer AD, Klungel OH. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. *J Clin Epidemiol*. 2015 Feb;68(2):112-21. doi: 10.1016/j.jclinepi.2014.08.011. Epub 2014 Nov 26. Review

414. Franken M, Stolk E, Scharringhausen T, de Boer A, Koopmanschap M. A comparative study of the role of disease severity in drug reimbursement decision making in four European countries. *Health Policy*. 2015 Feb;119(2):195-202. doi: 10.1016/j.healthpol.2014.10.007. Epub 2014 Oct 22. Review.

415. Schmidt AF, Klugkist I, Klungel OH, Nielen M, de Boer A, Hoes AW, Groenwold RH. Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs. *J Clin Epidemiol*. 2015;68:387-96. doi: 10.1016/j.jclinepi.2014.11.015. Epub 2014 Nov 28

416. De Boer A. Increased mortality by digoxin in patients with atrial fibrillation? *J Am Coll Cardiol*. 2015 Jan 20;65(2):220-1. doi: 10.1016/j.jacc.2014.09.081

417. Baranova EV, Verhoef TI, Asselbergs FW, de Boer A, Maitland-van der Zee AH. Genotype-guided coumarin dosing: where are we now and where do we need to go next? *Expert Opin Drug Metab Toxicol*. 2015;16:1-14. [Epub ahead of print]

418. Verhoef TI, Redekop WK, de Boer A, Maitland-van der Zee AH; EU-PACT group. Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands. *Pharmacogenomics*. 2015;16:101-14. doi: 10.2217/pgs.14.149.

419. Kreeftmeijer-Vegter AR, Dorlo TP, Gruppen MP, de Boer A, de Vries PJ. Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome. *Br J Clin*



Pharmacol. 2015;80:242-52. doi: 10.1111/bcp.12607.

420. Fazeli Farsani S, Souverein PC, Overbeek JA, van der Vorst MM, Knibbe CA, Herings RM, de Boer A, Mantel-Teeuwisse AK. Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands. *Br J Clin Pharmacol*. 2015;80:294-303. doi: 10.1111/bcp.12608.

421. Van Hoesen DA, Blom MT, Bardai A, Souverein PC, De Boer A, Tan HL. Reduced pre-hospital and in-hospital survival rates after out-of-hospital cardiac arrest of patients with type-2 diabetes mellitus: an observational prospective community-based study. *Europace*. 2015 May;17(5):753-60. doi: 10.1093/europace/euv014.

422. Fazeli Farsani S, Souverein PC, van der Vorst MM, Knibbe CA, de Boer A, Mantel-Teeuwisse AK. Chronic comorbidities in children with type 1 diabetes: a population-based cohort study. *Arch Dis Child*. 2015;100:763-8. doi: 10.1136/archdischild-2014-307654.

423. Veldhuis-Vlug AG, Oei L, Souverein PC, Tanck MW, Rivadeneira F, Zillikens MC, Kamphuisen PW, Maitland-van der Zee AH, de Groot MC, Hofman A, Uitterlinden AG, Fliers E, de Boer A, Bisschop PH. Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density. *Osteoporos Int*. 2015 Jul;26(7):2019-27. doi: 10.1007/s00198-015-3087-0.

424. Blom MT, Jansen S, de Jonghe A, van Munster BC, de Boer A, de Rooij SE, Tan HL, van der Velde N. In-Hospital Haloperidol Use and Perioperative Changes in QTc-Duration. *J Nutr Health Aging*. 2015;19:583-9. doi: 10.1007/s12603-015-0465-4.

425. Hazelbag CM, Klungel OH, van Staa TP, de Boer A, Groenwold RH. Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events. *Ann Epidemiol*. 2015;25:590-6. doi: 10.1016/j.annepidem.2015.03.019.

426. Marvig CL, Verhoef TI, de Boer A, Kamali F, Redekop K, Pirmohamed M, Daly AK, Manolopoulos VG, Wadelius M, Bouvy M, Maitland-van der Zee AH; EU-PACT consortium. Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. *Thromb Res*. 2015;136:69-75. doi: 10.1016/j.thromres.2015.04.026.

427. Leusink M, Vijverberg SJ, Koenderman L, Raaijmakers JA, de Jongste JC, Sterk PJ, Duiverman EJ, Onland-Moret NC, Postma DS, de Boer A, de Bakker PI, Koppelman GH, Maitland-van der Zee AH. Genetic variation in uncontrolled childhood asthma despite ICS treatment. *Pharmacogenomics J*. 2015 May 12. doi: 10.1038/tpj.2015.36.

428. Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Maitland-van der Zee AH; EU-PACT group. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. *Thromb Res*. 2015;136:94-100. doi: 10.1016/j.thromres.2015.04.034.

429. Warnier MJ, Rutten FH, Souverein PC, de Boer A, Hoes AW, De Bruin ML. Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol. *Pharmacoepidemiol Drug Saf*. 2015;24:701-8. doi: 10.1002/pds.3792.

430. Mahmoudpour SH, Asselbergs FW, de Keyser CE, Souverein PC, Hofman A, Stricker BH, de Boer A, Maitland-van der Zee AH. Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors. *Int J Clin Pharm*. 2015 Dec;37(6):1095-103. doi: 10.1007/s11096-015-0159-3.

431. Bronsveld HK, Ter Braak B, Karlstad O, Vestergaard P, Starup-Linde J, Bazelier MT, De Bruin ML, de Boer A, Siezen CL, van de Water B, van der Laan JW, Schmidt MK. Treatment with insulin (analogues) and breast cancer risk in diabetics: a systematic review and meta-analysis of in vitro, animal and human evidence. *Breast Cancer Res*. 2015 Aug 5;17(1):100. doi: 10.1186/s13058-015-0611-2.

432. Ahmadizar F, Fazeli Farsani S, Souverein PC, van der Vorst MM, de Boer A, Maitland-van der Zee AH. Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study. *Pediatr Diabetes*. 2015 Aug 11. doi: 10.1111/peidi.12302. [Epub ahead of print]

433. Van der Aa MP, Fazeli Farsani S, Knibbe CA, de Boer A, van der Vorst MM.

*J Diabetes Res*. 2015;2015:362375. doi: 10.1155/2015/362375. Epub 2015 Jul 27. Review.

Population-Based Studies on the Epidemiology of Insulin Resistance in Children. *J Diabetes Res*. 2015;2015:362375. doi: 10.1155/2015/362375. Epub 2015 Jul 27. Review.

434. Rianne M.F. van Schie, Talitha I. Verhoef, Anthonius de Boer, Felix J.M.

van der Meer, William K. Redekop, Tom Schalekamp and Anke-Hilse

Maitland-van der Zee. Pharmacogenetics of Coumarin Anticoagulant Therapy. In: "Preventive and Predictive Genetics: Towards Personalised Medicine" eds Grech et al. 2015;307-328 ISBN: 978-3-319-15343-8 and 978-3-319-15344-5 (eBook)

435. Bazargani YT, de Boer A, Schellens JH, Leufkens HG, Mantel-Teeuwisse AK. Essential medicines for breast cancer in low and middle income countries. *BMC Cancer*. 2015 Aug 18;15(1):591. doi: 10.1186/s12885-015-1583-4.
436. Kleijnen S, Fathallah M, van der Linden MW, Vancraeynest P, Dahmani B, Timoney A, De Boer A, Leufkens HG, Goettsch WG. Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments. *Value Health*. 2015;18:663-72. doi: 10.1016/j.jval.2015.03.1790.
437. Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PLoS One*. 2015 Sep 2;10(9):e0136324. doi: 10.1371/journal.pone.0136324. eCollection 2015.
438. Mahmoudpour SH, Asselbergs FW, Terreehorst I, Souverein PC, de Boer A, Maitland-van der Zee AH. Continuation of angiotensin converting enzyme inhibitor therapy, in spite of occurrence of angioedema. *Int J Cardiol*. 2015;201:644-645. doi: 10.1016/j.ijcard.2015.08.185.
439. Nielen JT, de Vries F, Dagnelie PC, van den Bemt BJ, Emans PJ, Lalmohamed A, de Boer A, Boonen AE. Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case-control study. *Br J Clin Pharmacol*. 2015 Sep 16. doi: 10.1111/bcp.12786.
440. de Boer A, Cohen AF. Digoxin and mortality: lessons for observational studies. *Br J Clin Pharmacol*. 2015 Sep 22. doi: 10.1111/bcp.12791.
441. Yska JP, van Roon EN, de Boer A, Leufkens HG, Wilfert B, de Heide LJ, de Vries F, Lalmohamed A. Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery: A Population-Based Cohort Study in the United Kingdom. *JAMA Surg*. 2015 Sep 30:1-8. doi: 10.1001/jamasurg.2015.2398. [Epub ahead of print]
442. Van der Zanden R, de Vries F, Lalmohamed A, Driessen JH, de Boer A, Rohde G, Neef C, den Heijer C. Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study. *PLoS One*. 2015 Oct 15;10(10):e0139367. doi: 10.1371/journal.pone.0139367. eCollection 2015. PMID:26468883
443. Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH. Correction: Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PLoS One*. 2015 Oct 22;10(10):e0141704. doi: 10.1371/journal.pone.0141704. eCollection 2015. PMID:26492353
444. Tran-Duy A, Vanmolkot FH, Souverein PC, Hoes AW, de Boer A, Stehower CD, de Wit NJ, Joore MA, de Vries F. Co-Administration of Proton Pump Inhibitors in Chronic Aspirin Users and the Risk of Adverse Cardiovascular Events: a Population-Based Cohort Study. *Value Health*. 2015 Nov;18(7):A378. doi: 10.1016/j.jval.2015.09.796. Epub 2015 Oct 20.
445. Mahmoudpour SH, Asselbergs FW, Souverein PC, de Boer A, Maitland-van der Zee A. Angiotensin Converting Enzyme Inhibitors Prescribing Pattern For Different Indications: A Population Based Study. *Value Health*. 2015 Nov;18(7):A402. doi: 10.1016/j.jval.2015.09.933. Epub 2015 Oct 20.
446. Leusink M, Onland-Moret NC, de Bakker PI, de Boer A, Maitland-van der Zee AH. Seventeen years of statin pharmacogenetics: a systematic review. *Pharmacogenomics*. 2016 Jan;17(2):163-80. doi: 10.2217/pgs.15.158. Epub 2015 Dec 15.
447. de Boer A, Cohen AF, Ferro A, Flockhart DA, Gilchrist A, Isbister G, Loke YK, Ross S, Somogyi AA, Webb AJ. Editors' Report for 2015, December 2015. *Br J Clin Pharmacol*. 2016 Jan;81(1):6-7. doi: 10.1111/bcp.12865
448. Boef AG, Souverein PC, Vandenbroucke JP, van Hylckama Vlieg A, de Boer A, le Cessie S, Dekkers OM. Instrumental variable analysis as a complementary analysis in studies of adverse effects: venous thromboembolism and second-generation versus third-generation oral contraceptives. *Pharmacoepidemiol Drug Saf*. 2016 Mar;25(3):317-24. doi: 10.1002/pds.3956
449. Schmidt AF, Groenwold RH, Amsellem P, Bacon N, Klungel OH, Hoes AW, de Boer A, Kow K, Maritato K, Kirpensteijn J, Nielen M. Which dogs with appendicular osteosarcoma benefit most from chemotherapy after surgery? Results from an individual patient data meta-analysis. *Prev Vet Med*. 2016 Mar 1;125:116-25. doi: 10.1016/j.prevetmed.2015.10.016.
450. Meulendijks D, Henricks LM, Amstutz U, Froehlich TK, Largiader CR, Beijnen JH, de Boer A, Deenen MJ, Cats A, Schellens JH. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. *Int J Cancer*. 2016

Jan 25. doi: 10.1002/ijc.30014.

451. Schmidt AF, Klungel OH, Nielen M, de Boer A, Groenwold RH, Hoes AW. Tailoring treatments using treatment effect modification. *Pharmacoepidemiol Drug Saf.* 2016 Feb 15. doi: 10.1002/pds.3965.

452. Tjin A Tsoi SL, de Boer A, Croiset G, Koster AS, Kusurkar RA. Unraveling Motivational Profiles of Health Care Professionals for Continuing Education: The Example of Pharmacists in the Netherlands. *J Contin Educ Health Prof.* 2016 Winter;36(1):46-54. doi: 10.1097/CEH

453. Verhaegh BP, de Vries F, Masclee AA, Keshavarzian A, de Boer A, Souverein PC, Pierik MJ, Jonkers DM. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. *Aliment Pharmacol Ther.* 2016 Mar 9. doi: 10.1111/apt.13583.

de Groot MC, Candore G, Uddin MJ, Souverein PC, Ali MS, Belitser SV, Huerta C, Groenwold RH, Alvarez Y, Slattery J, Korevaar J, Hoes AW, Roes KC, de Boer A, Douglas IJ, Schlienger RG, Reynolds R, Klungel OH, Gardarsdottir H. Case-only designs for studying the association of antidepressants and hip or femur fracture.

*Pharmacoepidemiol Drug Saf.* 2016 Mar;25 Suppl 1:103-13. doi: 10.1002/pds.3850.

454. Ali MS, Groenwold RH, Belitser SV, Souverein PC, Martin E, Gatto NM, Huerta C, Gardarsdottir H, Roes KC, Hoes AW, de Boer A, Klungel OH. Methodological comparison of marginal structural model, time-varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. *Pharmacoepidemiol Drug Saf.* 2016 Mar;25 Suppl 1:114-21. doi: 10.1002/pds.3864.

455. Uddin MJ, Groenwold RH, de Boer A, Gardarsdottir H, Martin E, Candore G, Belitser SV, Hoes AW, Roes KC, Klungel OH. Instrumental variables analysis using multiple databases: an example of antidepressant use and risk of hip fracture. *Pharmacoepidemiol Drug Saf.* 2016 Mar;25 Suppl 1:122-31. doi: 10.1002/pds.3863.

456. Uddin MJ, Groenwold RH, de Boer A, Afonso AS, Primates P, Becker C, Belitser SV, Hoes AW, Roes KC, Klungel OH. Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction. *Pharmacoepidemiol Drug Saf.* 2016 Mar;25 Suppl 1:132-41. doi: 10.1002/pds.3860.

457. Leusink M, Maitland-van der Zee AH, Ding B, Drenos F, van Iperen EP, Warren HR, Caulfield MJ, Cupples LA, Cushman M, Hingorani AD, Hoogeveen RC, Hovingh GK, Kumari M, Lange LA, Munroe PB, Nyberg F, Schreiner PJ, Sivapalaratnam S, de Bakker PI, de Boer A, Keating BJ, Asselbergs FW, Onland-Moret NC. A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. *Pharmacogenomics.* 2016 Apr;17(6):583-91. doi: 10.2217/pgs.16.8.

458. Uddin MJ, Groenwold RH, Ali MS, de Boer A, Roes KC, Chowdhury MA, Klungel OH. Methods to control for unmeasured confounding in pharmacoepidemiology: an overview.

*Int J Clin Pharm.* 2016 Jun;38(3):714-23. doi: 10.1007/s11096-016-0299-0.

459. Maagdenberg H, Vijverberg SJ, Bierings MB, Carleton BC, Arets HG, de Boer A, Maitland-van der Zee AH. Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.

*Paediatr Drugs.* 2016 Aug;18(4):251-60. doi: 10.1007/s40272-016-0176-2. Review.

460. Nielen JT, Emans PJ, Dagnelie PC, Boonen A, Lalmohamed A, de Boer A, van den Bernt BJ, de Vries F. Severity of Diabetes Mellitus and Total Hip or Knee Replacement: A Population-Based Case-Control Study. *Medicine (Baltimore).* 2016 May;95(20):e3739. doi: 10.1097/MD.0000000000003739.

461. Cohen AF, Pattanaik S, Kumar P, Bies RR, de Boer A, Ferro A, Gilchrist A, Isbister GK, Ross S, Webb AJ. Organised crime against the academic peer review system. *Br J Clin Pharmacol.* 2016 Jun;81(6):1012-7. doi: 10.1111/bcp.12992. No abstract available. Erratum in: *Br J Clin Pharmacol.* 2016 Aug;82(2):574.

462. Lalmohamed A, van Staa TP, Vestergaard P, Leufkens HG, de Boer A, Emans P, Cooper C, de Vries F. Statins and Risk of Lower Limb Revision Surgery: The Influence of Differences in Study Design Using Electronic Health Records From the United Kingdom and Denmark. *Am J Epidemiol.* 2016 Jul 1;184(1):58-66. doi: 10.1093/aje/kwv311.

463. Kleijnen S, Lipska I, Leonardo Alves T, Meijboom K, Elsada A, Vervolgyi V, d'Andon A, Timoney A, Leufkens HG, De Boer A, Goettsch WG. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. *Ann Oncol.* 2016 Sep;27(9):1768-75. doi: 10.1093/annonc/mdw233.

464. Mahmoudpour SH, Baranova EV, Souverein PC, Asselbergs FW, de Boer A, Maitland-van der Zee AH; PREDICTION-ADR consortium. Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink.

Br J Clin Pharmacol. 2016 Dec;82(6):1647-1659. doi: 10.1111/bcp.13090.

465. Tjin A Tsoi SL, de Boer A, Croiset G, Koster AS, Kusurkar RA. Factors Influencing Participation in Continuing Professional Development: A Focus on Motivation Among Pharmacists. J Contin Educ Health Prof. 2016 Summer;36(3):144-50. doi: 10.1097/CEH.0000000000000081.

466. Ahmadizar F, Vijverberg SJ, Arets HG, de Boer A, Lang JE, Kattan M, Palmer CN, Mukhopadhyay S, Turner S, Maitland-van der Zee AH. Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis. Eur Respir J. 2016 Oct;48(4):1063-1073. doi: 10.1183/13993003.00766-2016.

467. Ahmadizar F, Souverein PC, Arets HG, de Boer A, Maitland-van der Zee AH. Asthma related medication use and exacerbations in children and adolescents with type 1 diabetes. Pediatr Pulmonol. 2016 Nov;51(11):1113-1121. doi: 10.1002/ppul.23428.

468. Yasmina A, de Boer A, Deneer VH, Souverein PC, Klungel OH. Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period. Br J Clin Pharmacol. 2017 Mar;83(3):632-641. doi: 10.1111/bcp.13139.

469. Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT group. Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. J Thromb Haemost. 2017 Mar;15(3):454-464. doi: 10.1111/jth.13601.

470. Mahmoudpour SH, Veluchamy A, Siddiqui MK, Asselbergs FW, Souverein PC, de Keyser CE, Hofman A, Lang CC, Doney AS, Stricker BH, de Boer A, Maitland-van der Zee AH, Palmer CN; PREDICTION-ADR consortium. Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors. Pharmacogenet Genomics. 2017 Mar;27(3):112-119. doi: 10.1097/FPC.0000000000000264.

471. Baranova EV, Verhoef TI, Ragia G, le Cessie S, Asselbergs FW, de Boer A, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT group. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. J Thromb Haemost. 2017 Mar;15(3):465-472. doi: 10.1111/jth.13615.

472. van der Aa MP, Hoving V, van de Garde EM, de Boer A, Knibbe CA, van der Vorst MM. The Effect of Eighteen-Month Metformin Treatment in Obese Adolescents: Comparison of Results Obtained in Daily Practice with Results from a Clinical Trial. J Obes. 2016;2016:7852648. doi: 10.1155/2016/7852648.

473. Gieling E, van den Ham HA, van Onzenoort H, Bos J, Kramers C, de Boer A, de Vries F, Burden AM. Risk of major bleeding and stroke associated with the use of VKAs, NOACs and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol. 2017 Feb 16. doi: 10.1111/bcp.13265. [Epub ahead of print]

474. Bronsveld HK, Peeters PJ, de Groot MC, de Boer A, Schmidt MK, De Bruin ML. Trends in breast cancer incidence among women with type-2 diabetes in British general practice. Prim Care Diabetes. 2017 Feb 22. pii: S1751-9918(17)30024-4. doi: 10.1016/j.pcd.2017.02.001. [Epub ahead of print]

etc etc

**Projects** see my publications

**Memberships** Dutch society of Clinical Pharmacology and Biopharmacy  
Royal Dutch Society of Pharmacy  
Dutch Society of Epidemiology

**Other Relevant Information**